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917-19 What Are the Characteristics of Patients With Severe, 
Symptomatic, Mitral Regurgitation Who Are Denied 
Surgery?
Bernard Iung, Mariana Mirabel, David Messika-Zeitoun, Agnes Cachier, Eric Butchart, 
Gabriel Baron, Frank Vermeer, Alec Vahanian, Bichat Hospital, Paris, France
Background: Guidelines recommend surgery in patients who present with severe, 
symptomatic mitral regurgitation (MR). However, little is known regarding decision for 
surgery in current practice. We used the data from the Euro Heart Survey on valvular 
heart disease to identify the proportion and characteristics of patients with severe, 
symptomatic, MR who were denied surgery.
Methods: Among the 5001 pts included in the Euro Heart Survey on valvular heart 
disease between April and July 2001, 877 had isolated MR, of whom 546 had severe MR, 
deﬁned as MR grade ≥ 3/4, and 437 had severe MR and symptoms, i.e. dyspnea NYHA 
class II or greater and/or angina.
Results: Mean age of the 437 patients was 66±12 years, 201 (46%) being aged ≥70; 39% 
of patients were in NYHA class I-II, 46% in class III, and 15% in class IV, 35% of patients 
had signs of congestive heart failure at admission. Atrial ﬁbrillation was present in 141 
patients (32%). Etiology was degenerative in 238 (56%), rheumatic in 66 (15%), ischaemic 
in 40 (9%) endocarditis in 13 (3%), and other in 80 (18%). Left ventricular ejection fraction 
(LVEF) was 52±15%, it was <60% in 62% of patients and <30% in 7%. At least one 
comorbidity was present in 179 patients (41%). Coronary angiography was performed in 
245 patients (56%) and showed signiﬁcant coronary artery disease in 112 patients (46%). 
It was decided against surgery in 226 patients (52%). In multivariate analysis, age ≥ 70 
years (p=0.0001), LVEF < 60% (p=0.0002), congestive heart failure (p=0.0007), NYHA 
class II (p=0.01), and the presence of at least one comorbidity (p=0.01) were associated 
with the decision not to operate.
Conclusion: In this contemporary survey 1) Surgery was denied in as much as a 
half of patients with severe, symptomatic MR. 2) Older age and comorbidity might be 
valid grounds for deciding against surgery in certain cases. 3) Conversely, moderately 
decreased LVEF, congestive heart failure, and moderate symptoms (NYHA class II) 
should not lead to deny surgery according to current guidelines.
917-20 Functional Ischemic Mitral Regurgitation: Impact of Left 
Ventricular Function on Outcome
Eric Dumont, A. Marc Gillinov, Eugene H. Blackstone, Jeevanantham Rajeswaran, Alex 
S. Colafranceschi, Tomislav Mihaljevic, Cleveland Clinic Foundation, Cleveland, OH
Background: To determine the impact of global and regional left ventricular (LV) structural 
and functional abnormalities on survival and recurrence of mitral valve regurgitation after 
surgical annuloplasty for ischemic mitral regurgitation (MR).
Methods: From 11/1989 to 1/2005, 745 patients underwent isolated mitral valve 
annuloplasty for functional ischemic mitral regurgitation. All had previous myocardial 
infarction and grade 2+ (moderate, 12%) or more (88%) regurgitation; most had 3-system 
coronary artery disease (69%). From preoperative echocardiograms, graded wall motion 
abnormality was recorded in six regions, as was LV ejection fraction (43+/-15%), LV mass 
(144+/-43 g m2), LV systolic and diastolic volumes, and wall thicknesses. Survival was 
determined from systematic follow-up. All available postoperative echocardiograms were 
retrieved (n=1004) to assess mitral regurgitation.
Results: Hospital mortality was 5.1% (38/745), and 1-, 5-, and 10-year survivals were 
85%, 64%, and 39%, respectively. Smaller fractional shortening and larger posterior wall 
thickness were associated with early mortality (<30 days). No LV function or structure 
variables were associated with late mortality. Larger ventricular septal thickness was 
associated with higher likelihood of early return (<1 year) of MR. Larger LV mass index 
was associated with higher likelihood of late return of signiﬁcant MR. Within the year 
following annuloplasty, return of grade 2+ or higher MR was 40%.
Conclusions: Early survival following annuloplasty for ischemic mitral regurgitation is 
adversely affected by global LV dysfunction and post-infarct remodeling. During this time, 
mitral regurgitation returns in a substantial proportion of patients.These ﬁndings further 
emphasize the ventricular, rather than valvar, nature of this disease.
917-21 Favorable Effects of Additional Mitral Valve Repair 
on Ischemic Mitral Regurgitation and Left Ventricular 
Remodeling
Duk-Hyun Kang, Mi-Jeong Kim, Soo-Jin Kang, Se-Whan Lee, Eui-Seock Hwang, Jong-
Min Song, Kee-Jun Choi, Myeong-Ki Hong, Jae-Kwan Song, Seung-Jung Park, Asan 
Medical Center, Seoul, South Korea
We tried to test the hypothesis that additional mitral valve (MV) repair is superior to 
coronary artery bypass graft surgery (CABG) alone in reducing adverse remodeling of left 
ventricle (LV) by decreasing ischemic mitral regurgitation (MR) more effectively. Methods: 
A total of 60 consecutive patients with severe ischemic functional MR underwent CABG 
with concomitant MV repair (repair group, n = 36) or CABG only (CABG group, n = 24). 
End-systolic dimensions (ESD), end-diastolic dimensions (EDD) of LV were measured 
and end-systolic volumes (ESV), end-diastolic volumes (EDV), and ejection fractions 
(EF) of LV were calculated using biplane Simpson method. Degree of MR was graded 
from 0 to 3 by proximal isovelocity surface area method, and viability of LV was deﬁned 
as improvement of wall motion score with increase of EF > 5% on 1 year follow-up 
echocardiography.
Results: Clinical characteristics and baseline severity of MR were similar between two 
groups. The operative mortality of repair group and CABG group was 8.3% and 4.2% (p = 
ns). Ischemic MR was improved in all patients of repair group and 61% of patients in CABG 
group (p<0.001). In patients with viability (n = 37), severity of MR and LV size was signiﬁcantly 
decreased following operation in both groups. However, only repair group showed signiﬁcant 
decrease in severity of MR and LV size in patients without viability (Table).
Conclusions: MV repair is more effective at reducing ischemic MR and LV size 
independent of viability.
Severity of MR and LV size in patients without viability
CABG (n=8) Repair (n=15)
Baseline Follow-up Baseline Follow-up
MR grade 3.0 ± 0 2.8 ± 0.7 3.0 ± 0 1.0 ± 0.7**
ESD (mm) 53 ± 9 54 ± 10 50 ± 9 47 ± 9
EDD (mm) 65 ± 6 64 ± 8 64 ± 6 60 ± 7**
ESV (ml) 116 ± 41 115 ± 44 102 ± 56 80 ± 35
EDV (ml) 164 ± 46 158 ± 49 160 ± 56 128 ± 37*
EF (%) 30 ± 7 28 ± 8 38 ± 13 39 ± 11
*p<0.05, **p<0.01 versus baseline
917-22 Inﬂuence of Mitral Valve Morphology and Functional 
Disorder on the Repair of Functional Ischemic Mitral 
Insufﬁciency
Nan Wang, Ramesh Bansal, Nahidh Hasaniya, S. Chokkalingam, Puneet Dhawan, Dipal 
Patel, Anees Razzouk, Loma Linda University Medical Center, Loma Linda, CA
Objective: To determine the inﬂuence of functional ischemic mitral regurgitation (FIMR) 
subtypes on mitral valve repair (MVRpr).
Methods: From 10/01 to 2/05, 75 serial pts had MVRpr for FIMR. There were 41 (54.7%) 
pts with symmetrical (Sym) MV annular distortion (MVAD) and 34 (45.3%) pts with 
asymmetrical (Asym) MVAD. Ten (13.3%) Asym pts also had severe leaﬂet tethering. The 
groups were compared for differences in valvular morphology and function. Follow-up for 
survival and MR were also analyzed.
Results: Sym and Asym had different MV properties (Table 1) and hence required different 
MVRpr approach. In 38 (93%) Sym pts, posterior annuloplasty alone was sufﬁcient. All 
Asym pts had an asymmetrical annuloplasty plus medial commissuroplasty in 16 (47%) 
pts, artiﬁcial chords in 3 (9%) pts and sliding posterior leaﬂet commissuro-annuloplasty 
(SPLCA) in 5 (15%) pts with severe tethered leaﬂets. At follow-up (mean=1.86 yrs), 
Sym and Asym had similar survival (79+8%, 77+7%, p=.73) and freedom from MR>2+ 
(81+9%, 82+9%, p=.93).
Conclusion: FIMR differed in mechanism between Sym and Asym subsets. Sym pts 
had typical cardiomyopathy features: Lower EF, global ischemia, annular dilation and 
circularization, while most Asym pts had disproportionate inferior-posterior ischemia 
resulting in severe annular and leaﬂet distortion in the medial papillary muscle region. 
Remodeling technique, including SPLCA for severe tethered leaﬂet, at the medial 
commissural region is recommended in Asym pts.
Table 1. Preoperative Echocardiographic Asssessment
Mitral Valve and Left Ventricle Sym(n=41)
Asym
(n=34) p Value
AP annular dimension (cm) 3.53 +/- .05 3.29 +/- .05 <0.001
CC annular dimension (cm) 3.61 +/- .05 3.54 +/- .05 0.34
AP/CC ratio 0.98 +/- .01 0.93 +/- .02 <0.001
Leaﬂet restriction (mod/sev)
Asym restriction (sev)
9 (22%)
0 (0%)
16 (47%)
9 (26%)
0.02
<0.001
Antseptal or Lateral severe hypokinesis or worse 13 (32%) 7 (21%) 0.28
Inferior or Posterior severe hypokinesis or worse 19 (46%) 27 (79%) 0.003
LV ejection fraction (%) 22.8 +/- 2.0 39.1 +/- 2.2 <0.001
Central or Bicommissural origin 40 (98%) 0 (0%) <0.001
Medial or Lateral commissural origin 1 (2%) 34 (100%) <0.001
917-23 Mitral Valve Repair with a Novel Etiology-Speciﬁc 
Annuloplasty Ring for Ischemic Mitral Regurgitation: 
Early Echocardiographic Results from a Multi-center 
Study
Masao Daimon, Shota Fukuda, David Adams, Patrick M. McCarthy, A. Marc Gillinov, 
Alain Carpentier, Farzan Filsouﬁ, Vivian M. Abascal, Vera H. Rigolin, Anna Huskin, 
Michelle Langenfeld, Takahiro Shiota, Cleveland Clinic Foundation, Cleveland, OH, 
Mount Sinai Medical center, New York, NY
Background: Ischemic mitral regurgitation (IMR) is associated with asymmetric changes 
in annular and ventricular geometry. Surgical repair with standard, symmetric annuloplasty 
rings leaves up to 30% of patients with residual or recurrent mitral regurgitation (MR). 
The Carpentier-McCarthy-Adams IMR ETlogix Annuloplasty Ring (CMA ring) is the ﬁrst 
remodelling ring speciﬁcally designed to treat leaﬂet tethering and asymmetric annular 
dilatation. We used quantitative 2D echo to examine early results of mitral valve (MV) 
repair with the CMA ring in patients with IMR.
Methods: A total of 70 patients (64±11 yrs) with grade ≥ 2+ (Mean 3.1±0.8) IMR 
underwent MV repair with the CMA ring. We assessed the mitral annular diameter in the 
anterior-posterior dimension (MAD) and tethering area (TA) of the MV in 4-chamber (4ch), 
2-chamber (2ch) and long axis (LAX) views at mid-systole before and 3 to 5 days after 
surgery. The severity of MR was graded on a scale of 0-4.
Results: Following surgery, 68/70 (97%) patients had grade 0 or 1+ MR while 2 patients 
had 2+ MR (Mean 0.4±0.6). MV repair with the CMA ring signiﬁcantly reduced TA and MAD 
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in all 3 echo planes (Table). Left ventricular volumes were also signiﬁcantly decreased.
Conclusion: Surgical repair of IMR with the novel, asymmetric CMA ring provides 
excellent early results with effective reduction of MAD, leaﬂet tethering and LV volume. 
This novel, etiology-speciﬁc strategy may result in improved outcomes in IMR patients, 
including lower incidence of recurrent MR. 
Baseline 3-5 days after surgery p-value
LA area (cm2) 26.0 ± 7.0 22.2 ± 5.5 < 0.001
LVEDV (mL) 173 ± 73 151 ± 65 < 0.001
LVESV (mL) 109 ± 58 94 ± 50 < 0.001
Ejection fraction (%) 39.1 ± 10.7 40.2 ± 10.6 n.s
TA 4ch (cm2) 1.3 ± 0.5 0.6 ± 0.2 < 0.001
TA 2ch (cm2) 1.2 ± 0.4 0.6 ± 0.3 < 0.001
TA LAX (cm2) 1.5 ± 0.5 0.6 ± 0.2 < 0.001
MAD 4ch (cm) 3.0 ± 0.3 2.3 ± 0.3 <0.001
MAD 2ch (cm) 3.1 ± 0.3 2.5 ± 0.3 <0.001
MAD LAX (cm) 3.0 ± 0.4 2.1 ± 0.3 <0.001
MR grade 3.1 ± 0.8 0.4 ± 0.6 < 0.001
LA, left atrial; LVEDV and LVESV, left ventricular end-systolic and end-diastolic volume
 
917-24 Toward More Predictable Repair of Regurgitant Aortic 
Valves: A Logical, Segmental Approach
B. Gosta Pettersson, Adrian Crucean, Robert Savage, Lars G. Svensson, Sepehre 
Naﬁcy, A. Marc Gillinov, Eugene H. Blackstone, The Cleveland Clinic Foundation, 
Cleveland, OH
Background: Repair of regurgitant aortic valves is not widely accepted. We hypothesize 
that a logical, structured, segmental approach to morphology and repair will improve 
decision-making and success.
Methods: A systematic approach to valve analysis and repair was applied prospectively 
to 27 patients with bicuspid aortic valves and pure aortic regurgitation (AR). Segmental 
analysis by echocardiography and direct inspection included recording of 1) cusp 
morphology (size, thickness, mobility, integrity), 2) commissural structure (splaying, 
fusion, attachment), and 3) root geometry (left ventricular outﬂow tract, anulus, sinuses, 
STJ, ascending aorta). Surgical manipulation to correct each abnormality was based on 
this segmental valve analysis.
Results: 21 valves (78%) were repaired and 6 (22%) replaced. Morphology and causes 
of regurgitation related primarily to cusp morphology and commissure structure and 
included cusp restriction and/or prolapse and commissural separation or splaying; root 
pathology was unimportant. Repair procedures directed correspondingly included cusp 
procedure 100% (debridement 52%, extension 10%, plication 86%, triangular resection 
14%, patch 19%, suture 14%, margin reinforcement 5%), commissural procedure 81% 
(raphe resection 10%, commissurotomy 10%, commissuroplasty 57%, resuspension 5%), 
and root procedure (plication 38%, wedge aortoplasty 10%). Insufﬁcient normal cusp 
tissue was the main limiting factor for successful repair. Echocardiography illustrates this 
by greater “cusp tissue normality index” (diastolic vs. systolic cusp area) of successfully 
repaired valves compared with replaced ones: right 52±11% vs. 19±3.3%; left, 52±17% 
vs. 24±12%; non-coronary 61±18% vs. 26±7.3%.
Conclusions: Systematic and segmental analysis of morphology and approach to surgical 
manipulations facilitates aortic valve repair. Initial application of this paradigm suggests 
mobile cusp tissue is a key determinant of repairability of bicuspid aortic valves.
917-25 Cerebrovascular Thromboembolic Events After Mitral 
Valve Repair: Implication for Treatment of Patients with 
Mitral Regurgitation
Antonio Russo, William K. Freeman, Thoralf M. Sundt, III, Robert D. Brown, Jr., Maurice 
E. Sarano, Mayo Clinic, Rochester, MN
Background: Mitral valve repair (MRep) improves survival after surgery of mitral 
regurgitation (MR) in comparison to mitral mechanical prosthesis (MMP) and bioprosthesis 
(MBP). However, it is unclear if post-operative risk of cerebrovascular thromboembolic 
events (Cv-TE) is affected by MRep.
Methods: We studied 1344 consecutive patients (aged 65±12 years, 62% male) after 
surgery of MR (897 MRep, 231 MMP and 216 MBP) performed from 1980 to1995. During 
a median follow up of 6.7±4.4 years, the total number of Cv-TE was 210: 112 in MRep, 64 
in MMP and 34 in MBP. The incidence of Cv-TE was assessed by yearly linearized rate.
Results: In the ﬁrst 30 days, incidence of Cv-TE was 29.6%/year in MRep, 22.1%/year 
in MMP and 59.9%/year in MBP (MRep vs MMP and MBP P=NS). Between 30 and 180 
days, incidence of Cv-TE was 4.6%/year in MRep, 6.3%/year in MMP and 4.8%/year in 
MBP (MRep vs MMP and MBP P= NS). After 180 days, incidence of Cv-TE was 1.4%/
year in MRep, 3.7%/year in MMP and 1.9%/year in MBP (MRep vs MMP P=0.000011; 
MRep vs MBP P=NS).
Conclusions: MRep is associated with lower long-term incidence of Cv-TE than MMP 
and with a smaller beneﬁt compared to MBP. However, there is a high rate of Cv-TE in all 
types of surgeries, including MRep, within the ﬁrst month post-op, that extends to the ﬁrst 
6 months after surgery of MR.
Therefore, MRep should be the preferred correction of MR to minimize the Cv-TE risk 
but requires relatively prolonged anticoagulation for Cv-TE prevention in the ﬁrst 6 post-
operative months.
917-26 Mitral Valve Abnormalities in Patients Undergoing 
Myectomy: Echocardiographic Features, Surgical 
Therapies and Outcomes
Ryan K. Kaple, Ross T. Murphy, Angela York, Harry M. Lever, Bruce W. Lytle, Eugene H. 
Blackstone, Nicholas G. Smedira, Cleveland Clinic Foundation, Cleveland, OH
Objectives: Deﬁne the echocardiographic features of mitral valve (MV) pathology in 
hypertrophic cardiomyopathy (HCM) , their impact on surgical therapies and outcomes.
Methods: From 1976 to 2004, of 606 patients with symptomatic left ventricular outﬂow 
tract obstruction (LVOTO) who were managed surgically, 115 had a concomitant mitral 
valve (MV) procedure. Qualitative and quantitative analysis was performed on 1,018 
transthoracic, transesophageal and intra-operative echocardiograms.
Results: Mean LVOTO peak gradient was 89 mmHg ± 49, and systolic anterior motion 
was present in 87% of patients. MV abnormalities were characterized as prolapse in 
57 (53%), leaﬂet tethering in 17 (16%), papillary muscle or chordal abnormalities in 
21(20%), calciﬁed/thickened leaﬂets in 61 (57%), and elongated leaﬂets in 51 (48%). 
Patients undergoing MV replacement (n=48) vs repair (n=67) had more calciﬁed/
thickened leaﬂets (73% vs 45%, P<0.01), less elongated leaﬂets (29% vs 61%, P<0.01), 
and similar degenerative/prolapsing leaﬂets (53% each) and anomalous papillary muscle/
chordae attachments (16% vs 24%). The anterior mitral leaﬂet was longer in the repair vs 
replacement group (3.0 vs 2.5 cm, P<0.01). MV replacement patients were older, more 
symptomatic (higher NYHA class) with more renal dysfunction, anemia, prior MI, and 
coronary artery disease. There were 3 in-hospital deaths (2.6%). Survival at 5 and 10 
years was 80% and 75%, respectively and unadjusted survival was not different in the 
repair vs the replacement group.
Conclusions: Intrinsic mitral valve pathology is commonly observed in HCM patients 
with symptomatic obstruction undergoing myectomy. Echocardiography can identify MV 
features predictive of mitral valve repair. The relative contribution of MV replacement and 
comorbidities on outcome needs further evaluation.
917-27 Initial Experience of New Three-Dimensional 
Annuloplasty Ring for Functional Tricuspid 
Regurgitation
Shota Fukuda, A. Marc Gillinov, Patrick M. McCarthy, Masao Daimon, Jong-Min Song, 
Mi-Seung Shin, James D. Thomas, Takahiro Shiota, Cleveland Clinic Foundation, 
Cleveland, OH, Northwest Memorial Hospital, Chicago, IL
Background. Edward MC3 tricuspid valve (TV) annuloplasty ring, which has 3-
dimensional structure to preserve the physiologic function of TV annulus, was recently 
developed and introduced in patients.
Purpose. To investigate the early- and mid-term outcome of TV annuloplasty with the 
Edward MC3 ring in patients with functional tricuspid regurgitation (TR).
Methods. Consecutive 149 patients with functional TR had 2-dimensional 
echocardiography before and early (5±4 days) after TV annuloplasty with the Edward 
MC3 ring. 21 patients (14%) were followed for >1 year (16±4 months) after surgery. 
Left ventricular ejection fraction (LV EF) was determined with Simpson method. Right 
ventricular (RV) systolic function was assessed visually by echocardiographic experts 
and RV dysfunction was qualitatively classiﬁed from mild (1+) to severe (4+). The severity 
of TR was graded from 1+ to 4+ using color Doppler methods.
Results. TR was reduced early after TV annuloplasty (p<0.001) and stayed at the same 
level during follow-up period. RV function decreased early postoperatively (p<0.001), and 
then showed a tendency to improve during follow up (table). LV EF did not change during 
the follow-up period. 3 patients (2%) had TV replacement 19±9 days after initial surgery.
Conclusions. TV annuloplasty with the Edward MC3 ring was effective in the treatment 
of functional TR. This new surgical treatment may result in improved outcomes in patients 
with function TR with the potential to preserve RV function.
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Before 
annuloplasty
Early 
postoperatively
More than 1 year after 
annuloplasty
LV EF (%) 42.0±17.5 38.4±15.9 35.7±18.1
The degree of RV 
dysfunction 0.9±1.2 1.7±1.4 1.3±1.5
The severity of TR 2.8±0.8 1.0±0.8 0.9±0.8
POSTER SESSION
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Adult Cardiothoracic Surgery
Sunday, March 12, 2006, 1:30 p.m.-5:00 p.m.
Georgia World Congress Center, Hall B1
Presentation Hour: 3:30 p.m.-4:30 p.m.
940-19 A Randomized Double Blind, Placebo Controlled Trial to 
Investigate the Effect of Intravenous N-Acetylcysteine 
in Preventing Renal Dysfunction Following 
Cardiopulmonary Bypass in High Risk Patients
Veena Guru, David Naimark, Avita Sooknanan, John Omura, Judy Lin, Senri Miwa, 
Cameron Guest, Claude Laﬂamme, Gideon Cohen, George Christakis, Bernard 
Goldman, Stephen E. Fremes, SWCHSC, Toronto, ON, Canada
Background: N-acetylcysteine (NAC) replenishes glutathione, a precursor in the 
degradation of free oxygen radicals causing renal damage during cardiopulmonary 
bypass (CPB). This study evaluates the effectiveness of NAC in preventing postop renal 
dysfunction in high-risk patients. 
Methods: A randomized, stratiﬁed (valve, CABG, and preop renal insufﬁciency), double 
blind, placebo trial was approved by ethics, and informed consent was obtained. Patients 
exposed to CPB were eligible if they had preop renal dysfunction (Serum creatinine 
(Cr)>139µmol/L, glomerular ﬁltration rate (GFR)<51ml/min) or risk for postop renal 
dysfunction. 106 were randomized (54 placebo, 52 NAC). The treatment group received 
IV NAC (150mg/kg bolus at induction, and 50mg/kg/hr during CPB). The primary outcome 
was: change in Cr (baseline-peak postop; DIFF). The secondary outcomes included: 
GFR change, urea rise, postoperative dialysis, troponin T rise, and composite adverse 
outcomes (death, dialysis, ECG MI, low output syndrome (LOS=inotropic use+/-postop 
IABP), reoperation, and stroke. Chi-square tests were used for categorical variables and 
paired t-tests for continuous v ariables. 
Results: There were no differences in primary outcomes between trial arms (Table 1). 
There was a higher rate of stroke in the treatment arm. 
Conclusion: This trial suggests that perioperative IV NAC does not provide beneﬁt as 
compared to a saline bolus in patients at risk for renal dysfunction undergoing surgery 
involving CPB.
Outcomes in placebo versus NAC groups (95% C.I.)
Outcome Placebo n=54 NAC n=52 Difference or p-value
Cr DIFF (umol/L) 50 (31, 69) 43 (28,59) 6 (-18, 31)
GFR DIFF (mL/min) -0.17 -0.19 0 (-0.1, 0.1)
Urea DIFF 4 (3, 5) 4 (2, 5) 0 (-2, 2)
Dialysis 2% 8% 0.16
Trop T 0.93 0.74 0.2 (-0.13, 0.52)
Post-op LOS 26% 21% 0.56
CVA (CTSCAN) 0% 8% 0.04
Death 4% 4% 0.97
Composite 37% 34% 0.79
 
940-20 Bedside Tool to Predict Risk of Postoperative Dialysis: 
Results in 358,296 Patients Undergoing Coronary 
Bypass Surgery
Rajendra H. Mehta, Joshua D. Grab, Sean M. O’Brien, Charles Bridges, James Gammie, 
Constance Haan, Bruce Ferguson, Eric D. Peterson, Duke Clinical Research Institute, 
Durham, NC
Background: The need to initiate dialysis after bypass surgery (CABG) is a serious 
complication adversely impacting patient outcomes, quality of life, and resource utilization. 
Rapid, accurate estimation of an individual patient’s risk for postoperative dialysis is 
needed for clinical decision making and patient counseling.
Methods: Using the STS National Database, we analyzed 358,296 patients undergoing 
isolated CABG between 2002 and 2004 who were not on dialysis prior to surgery. Logistic 
regression was used to identify major predictors of postoperative dialysis. The full model 
was then simpliﬁed, with model coefﬁcients converted to an additive risk score.
Results: Postoperative dialysis was needed in 4,041 patients after CABG (1.1%). 
Independent preoperative risk factors included age, gender, diabetes, lung disease, 
myocardial infarction, shock, NYHA class and preoperative serum creatinine. The C index 
of the model was 0.83, showing excellent discrimination. Individual patient risk scores 
ranged from 0 to 64. The ﬁgure demonstrates the ability of the risk scores to identify those 
with low, modest, and high risk for postoperative dialysis.
Conclusions: Our study identiﬁes the major patient risk factors for postoperative 
dialsyis following CABG. These have been converted into a simple, accurate bedside 
risk tool. This should faciliate improved clinician-patient discussions regarding risks of 
postoperative dialysis.
940-21 Simple Risk Model to Predict Surgical Mortality in 
Acute Type A Aortic Dissection: The IRAD Score
Vincenzo Rampoldi, Santi Trimarchi, Kim A. Eagle, Christoph Nienaber, Jae Oh, 
Eduardo Bossone, Truls Myrmel, Carlo De Vincentiis, Jeanna V. Cooper, Jianming Fang, 
Rossella Fattori, Udo Sechtem, Eric M. Isselbacher, Policlinico S. Donato, S. Donato 
Milanese, Italy, University of Michigan, Coordinating Center for IRAD, Ann Arbor, MI
Background:
Surgical mortality for acute type A aortic dissection (AAD) is frequently due to clinical 
preoperative conditions. A predictive score to identify risk of death may be helpful to assist 
surgeons, who are considering whether or not to proceed with surgical correction.
Methods:
A comprehensive analysis was completed of 290 clinical variables and their relation to 
surgical outcomes in 682 with acute Type A aortic dissection, enrolled in the International 
Registry of Acute Aortic Dissection (IRAD) from 1996-2003. Two different models were 
performed, ﬁrst evaluating demographic, history, and preoperative variables as symptoms, 
signs and diagnostic methods. The ﬁnal model also included intraoperative hemodynamic 
and surgical variables. A bedside risk prediction tool was developed.
Results:
The overall in-hospital surgical mortality was 23.9%. Independent preoperative predictors 
of mortality in the ﬁrst model were age > 70 years (OR 1.92; 95% CI, 1.14 to 3.22; p 0.01), 
prior cardiac surgery (OR 1.93; 95% CI, 0.98 to 3.78; p 0.05), hypotension (SBP < 100 
mmHg) or shock (SBP < 80 mmHg) at presentation (OR 3.10; 95% CI, 1.86 to 5.17; p 
<0.0001), migrating pain (OR 2.38, 95% CI, 1.29 to 4.37; p 0.005), cardiac tamponade 
(OR 2.72; 95% CI, 1.51 to 4.89; p 0.0008), any pulse deﬁcit (OR 1.74; 95% CI, 1.05 to 
2.89; p 0.03), and ECG with ﬁndings of myocardial ischemia and/or infarction (OR 1.79; 
95% CI, 1.03 to 3.08; p 0.03). C-Statistic for this model was 0.76. In the second model, 
predictors of surgical death included intraoperative hypotension (OR 4.06; 95% CI, 2.31 
to 7.15; p <0.0001), and right ventricle dysfunction at surgery (OR 6.12; 95% CI 2.60 to 
14.55; p <0.0001). Independent predictor for a favorable surgical outcome was the right 
hemiarch replacement (OR 0.50; 95% CI, 0.27 to 0.92; p 0.02); C-Statistic for the second 
model was 0.81.
Conclusions:
Surgery in unstable patients with AAD is often unsuccessful and for certain individuals 
can be futile. The IRAD risk model predicts in-hospital mortality using a mathematical 
model. This tool may be useful for physicians and patients as they consider the pro’s and 
con’s of embarking on high risk surgery.
940-22 Long-Term Outcomes of Elective Abdominal Aortic 
Aneurysm Repair in Octogenarians
Tetsuo Kamiishi, Satoshi Takeshita, Hitoshi Matsuda, Satoshi Kasai, Koichi Akutsu, 
Tokio Hayashi, Hitoshi Ogino, Hiroshi Nonogi, National Cardiovascular Center, Osaka, 
Japan
Background: Decision-making in regard to elective repair of abdominal aortic aneurysms 
(AAA) requires careful assessment of rupture risk, operative mortality, and life expectancy. 
However, for octogenarians, limited information is available regarding the risk of elective 
AAA repair as well as its long-term beneﬁt. The purpose of this study was to evaluate 
early mortality and long-term survival of patients more than 80 years of age undergoing 
elective repair of AAA.
Methods: A total of 85 octogenarians (mean age 82.6 years, male: 80%) who underwent 
elective repair of AAA in our hospital from April 1981 through October 2000 were followed-
up for an average of 52.3 months.
Results: At baseline, 2 patients had previous myocardial infarction (2.4%), 2 cerebral 
infarction (2.4%), and 4 renal dysfunction (4.7%). Seventy-nine patients had infrarenal 
(92.9%), 3 juxtrarenal (3.5%), and 3 suprarenal (3.5%) AAAs. The mean AAA diameter 
was 6.2 cm. Aortic repair consisted of aortic bifurcation grafts in 68 patients (80%) 
and tube grafts in 17 (20%). Thirty-day mortality rate was 1.2%: one patient died of 
anaphylaxic shock. Other operative complications were observed in 3 patients (3.5%), 
which included dissection of iliac artery, acute renal failure, and pneumonia. One-, three-, 
ﬁve-, and ten-year survival rates were 85.9%, 63.5%, 36.5%, and 3.52%, respectively 
(operative mortality included).
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Conclusions: Elective repair of AAA in octogenarians is safe and durable. Long-term 
survival appears to be similar to that of a reported age-matched population. Repair of 
AAA should not be withheld on the basis of advanced age alone.
940-23 Septal Myectomy: 324 Consecutive Procedures Without 
a Mortality
Nicholas G. Smedira, Harry M. Lever, Michelle Miluk, Gita Krishnaswamy, Glynis Laing, 
Maran Thamilarasan, Bruce W. Lytle, Eugene H. Blackstone, Eric J. Topol, Cleveland 
Clinic Foundation, Cleveland, OH
Background: Septal myectomy is considered deﬁnitive therapy for patients with 
hypertrophic obstructive cardiomyopathy. This abstract examines outcomes after 324 
consecutive myectomies performed between 1994 and 2004.
Methods: Retrospective chart review of in-hospital events and social security death index 
(SSDI) evaluation of survival. Mean follow-up was 2.9 years.
Results: Operations consisted of isolated septal myectomy in 308 cases and 16 
myectomy with pulmonary vein isolation. The mean age was 50 ±14 years and 53% were 
male. Preoperative mean septal thickness was 2.3 cm ± 0.5 with a peak left ventricular 
outﬂow tract gradient of 67 ±41 mmHg . The median duration of intubation, ICU and 
postoperative stay was 6 hours and 1 and 6 days, respectively. There were no hospital 
deaths. Two intraoperative ventricular septal defects were repaired and reoperation was 
required in 2 patients to replace the mitral valve and 2 needed pericardial windows. Atrial 
ﬁbrillation developed in 31% of patients. Pacemakers were inserted in 22 (6.8%) patients 
and in only 3.8% for patients without conduction abnormalities on preoperative EKG. 
There were 9 late deaths; Kaplan-Meier survival curve is shown. 
Conclusion: Isolated septal myectomy is an extremely safe operation with little morbidity 
and no mortality and should be considered the ﬁrst choice in the treatment of symptomatic 
patients with hypertrophic obstructive cardiomyopathy.
940-24 Use and Effectiveness of Perioperative Cardiac Medical 
Therapy Among Patients Undergoing Coronary Artery 
Bypass Graft Surgery
Kristian B. Filion, Louise Pilote, Elham Rahme, Mark J. Eisenberg, Jewish General 
Hospital/McGill University, Montreal, PQ, Canada
Background: Previous studies have demonstrated that cardiac medical therapy is 
associated with improved clinical outcomes in non-cardiac surgery. However, the use 
and effectiveness of these agents among patients undergoing CABG remains under 
investigated.
Methods:  We described the in-hospital medication use among 2,389 consecutive 
patients who underwent CABG at 3 North American hospitals. Demographic, clinical, and 
medication use information was extracted from resource and cost accounting systems 
at each hospital. We examined use of aspirin, ACE inhibitors, beta-blockers, and statins 
during the following 7 in-hospital periods: admission, pre-surgery, the day before surgery, 
the day of surgery, the day after surgery, post-surgery, and discharge. We also identiﬁed 
patients with complications and performed a matched case-control study to examine the 
effectiveness of the use of these medications at preventing cardiac events.
Results: Medication use throughout hospitalization was low among patients undergoing 
CABG. Use of ACE inhibitors and statins on the day of surgery was <10%, while aspirin 
and beta-blockers use on the day of surgery was 43.0% and 42.9%, respectively. The use 
of cardiac medical therapy at hospital discharge was also low. Aspirin had the highest 
use at discharge (74.9%) while ACE inhibitors had the lowest use at discharge (23.0%). 
After adjusting for patient-level differences, there was a trend associating the use of beta-
blockers (odds ratio (OR)=0.70, 95% conﬁdence interval (CI)=0.46-1.05, p=0.09) and 
statins (OR=0.55, 95% CI=0.28-1.09, p=0.09) throughout the perioperative period with a 
decrease in in-hospital events. Use of beta-blockers on the day after surgery (OR=0.62, 
95%CI=0.48-0.86, p=0.002) was also associated with improved outcomes.
Conclusion: In-hospital cardiac medical therapies are underused among patients 
undergoing CABG. Perioperative use of beta-blockers and statins may improve in-hospital 
outcomes.
940-25 Trends and Predictors of Outcome in Circulatory Arrest 
for Adult Cardiac Surgery: A Decade of Experience 
(1996-2005)
Steve K. Singh, Veena Guru, Stacey B. O’Blenes, Gideon N. Cohen, George T. 
Christakis, Bernard S. Goldman, Stephen E. Fremes, Sunnybrook and Women’s College 
Health Sciences Centre, Toronto, ON, Canada
BACKGROUND: Many strategies used during circulatory arrest (CA) for surgery of the 
ascending aorta and arch are aimed at reducing death and stroke. This study describes 
changes in operative indications and processes over time and their impact on outcomes. 
These high risk operations are infrequent. Few studies are in the literature and their 
sample sizes are small and often involve the pediatric population.
METHODS: All adult patients requiring CA at our institution between 1996-2005 were 
identiﬁed from a prospectively collected clinical database. Further clinical and operative 
data were attained by chart review.
RESULTS: All 239 patients identiﬁed (mean age 65) were reviewed. Patient preoperative 
characteristics were similar over time. Degree of hypothermia and length of cross clamp, 
bypass and CA times, were similar over time. Other trends in operative characteristics 
and outcomes are shown in Table 1. Table 1 also lists the predictors of death based on 
a rigorous multivariate logistic model (C-statistic 0.84). Multivariate analysis for death 
or stroke (C-statistic 0.81) had similar results. No predictor was seen for stroke alone 
(C-statistic 0.74).
1996-1998, 
n=51
1999-2001, 
n=82
2002-2005, 
n=106 P-value
Indication:
Aneurysm
Dissection
Atherosclerotic Aorta
41.2%
39.2%
3.9%
41.5%
41.5%
7.3%
66.0%
18.9%
12.3%
0.001
0.001
NS
Concomitant:
Coronary bypass grafting
Bentall
Valve procedure
5.9%
23.5%
43.1%
17.1%
13.4%
45.1%
19.8%
14.2%
60.4%
0.01
NS
0.05
Any cerebral perfusion
Retrograde
Antegrade
56.9%
54.9%
2.0%
62.2%
61.0%
1.2%
66.6%
41.5%
15.1%
NS
0.02
<0.001
Arterial cannulation
Aorta
Femoral
Axillary
19.6%
80.4%
0.0%
39.0%
57.3%
3.7%
66.0%
17.9%
16.0%
<0.001
<0.001
<0.001
Stroke (in-hospital) 9.8% 7.3% 6.6% NS
Death (in-hospital) 30.6% 20.0% 13.6% 0.04
Predictor of Death: Odds ratio 95% C.I. P-value
Highest CA time tercile
Emergent case
Era (1996-1998)
Older Age
Prolonged bypass time
Retrograde cerebral 
perfusion
4.0
3.1
2.5
1.1
1.01
0.2
1.1-11.4
1.0-9.6
1.1-5.9
1.0-1.1
1.00-1.02
0.1-0.5
0.001
0.05
0.03
<0.001
0.001
<0.001
CONCLUSION: While the indications for CA have changed over time, era, operative 
characteristics, and processes such as the use of retrograde cerebral perfusion, have 
signiﬁcantly impacted survival. This is the largest cohort in the literature, contemporary, 
and relevant to the adult surgical population.
940-26 Short- and Long-term Outcomes of Cardiac Surgery for 
Observant Jehovah Witnesses
Mariano E. Brizzio, Eugene H. Blackstone, Gita Krishnaswamy, Michael S. Lauer, 
Cleveland Clinic Foundation, Cleveland, OH
Objectives: Cardiac surgeons may be reluctant to operate on observant Jehovah 
Witnesses (JW) because they refuse transfusions. We sought to assess short- and 
long-term risks in such patients, with comparisons to non-JW patients who did or did not 
receive blood transfusions.
Methods: Over 20 years, 228 JW adults who refused blood transfusion underwent 
cardiac surgery (67% CABG, 22% aortic valve surgery, 19% mitral valve surgery). Using 
propensity matching on 23 variables, we identiﬁed for each JW patient 10 controls from 2 
pools: 27,285 non-JW patients who did not receive transfusion and 35,813 who did.
Results: Among JW patients, 8 returned to the OR for bleeding (3.5%), 11 had respiratory 
insufﬁciency (4.8%), 6 had stroke (2.6%), and 7 died in-hospital (3.1%). During a mean 
of 8 years of follow-up, there were 80 deaths among JW patients. Compared with non-
JW matched non-transfusion controls, JW patients returned to the operating room for 
bleeding more often (3.5% vs. 0.4%, P<.0001) and experienced more in-hospital deaths 
(3.1% vs. 0.8%, P=.0009); however, risk of long-term death was only slightly increased 
(Figure). Compared with non-JW matched transfusion controls, JW patients had similar 
occurrence of in-hospital death (3.1% vs. 3.8%, P=.6) and slightly lower long-term risk 
of death.
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Conclusion: Although JW patients undergoing cardiac surgery might be at increased risk 
for in-hospital complications, long-term survival is comparable to non-JW patients who 
have or have not had blood transfusions.
940-27 The Long-Term Outcomes of Patients With Severe Left 
Ventricular Dysfunction Following Coronary Artery 
Bypass Graft (CABG) Surgery
Veena Guru, Stephen E. Fremes, Jack V. Tu, Institute For Clinical Evaluative Sciences, 
Toronto, ON, Canada, Sunnybrook and Women’s Health Sciences Centre, Toronto, ON, 
Canada
Introduction: Trial evidence suggests a mortality beneﬁt for patients with left ventricular 
dysfunction undergoing surgical revascularization. Our study understands the long term 
outcomes for patients with left ventricular function undergoing coronary artery bypass 
graft (CABG) surgery at a population level.
Methods: This was a retrospective population based cohort study (n=65,965 patients) 
using clinical data for all who underwent isolated CABG in the province between 1991-
2002 with outcomes obtained through linkage to administrative databases. The primary 
outcomes included repeat revascularization (angioplasty, bypass surgery), cardiac 
readmission (unstable angina, congestive heart failure, myocardial infarction), and death. 
Multivariable Cox models were used to assess the effect of left ventricular grade (Grade 
1>=50% n=27,893 , Grade2 35-49% n=24,137, Grade 3 20-34% n=11,318 , Grade 4 
<20% n=2,617).
Results: Patients with poor LV function (Grade 3 or 4) had higher proportions of males, 
comorbidity, unstable angina at presentation, congestive heart failure, and previous 
bypass surgery. Grade 4 left ventricle conferred a statistically signiﬁcant (p<0.0001) 
increased risk for all outcomes including repeat revascularization (HR 2.1), cardiac 
hospital admissions (HR 1.6, HR 2.8 for CHF speciﬁcally), death (HR 2.5), and a 
composite of these outcomes (HR 1.6).
Conclusion: This is the ﬁrst population based observational study to quantify the long 
term prognosis of patients with severe left ventricular function (Grade 4 left ventricle) out 
to ten years following surgical revascularization. Adjunctive therapies to revascularization, 
such as stem cell transplantation may help to impact on the extremely poor outcomes for 
these patients.
ORAL CONTRIBUTIONS
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803-4 Valvular Heart Disease Surveillance in the United 
States, 1980-2000
Hylan D. Shoob, Janet B. Croft, Carma Ayala, George A. Mensah, Centers for Disease 
Control and Prevention, Atlanta, GA
Background: Valvular Heart Disease (VHD) impacts morbidity and mortality in US adults 
but few national population-based data on VHD have been published.
Methods: VHD may be reported secondary to other diseases; therefore, multiple cause 
of death information from death certiﬁcates was used to assess deaths with VHD as any 
of 20 contributing causes in 1980-2000. The annual National Hospital Discharge Survey, 
which includes information on discharges from a US sample of non-Federal short-stay 
hospitals, was used to assess VHD as any of 7 hospital diagnoses in 1980-2000.
Results: Death rates (per 100,000) for VHD increased from 1980 to 2000 (9.1 to 15.5). Death 
rates increased from 11.2 in 1980 to 17.5 in 2000 in men and doubled from 7.5 to 14.2 in 
women. Death rates were higher for whites than blacks (9.2 in 1980 and 16.4 in 2000 vs. 7.9 
and 11.3, respectively). Of all VHD deaths in 1980 and 2000, ages >65 years accounted for 
79.7% and 89.8%, respectively. Hospital rates (per 100,000) with VHD doubled from 152.9 
in 1980 to 330.9 in 2000 and were higher for women than men. Of all VHD hospitalizations 
in 1980 and 2000, respectively, women accounted for 58.2% and 62.5%; ages >65 years 
accounted for 57.9% and 71.8%; and mitral valve involvement increased from 43.7% to 
60.3% while aortic valve involvement declined from 48.2% to 37.0%. Valve involvement 
in 2000 included tricuspid (4.5%), unspeciﬁed (3.3%) and pulmonary (0.7%). About 5.5% 
in 1980 and 6.5% in 2000 of all VHD hospitalizations involved procedures for valves and 
septa valve; replacement occurred in about 5% each year. The most common ﬁrst-listed 
diagnoses for all hospitalizations with any mention of VHD in 1980 and 2000, respectively, 
were VHD (49.8% and 25.7%), coronary heart disease (32.0% and 37.4%), and heart 
failure (16.0% and 35.8%); acute and chronic rheumatic heart disease and endocarditis 
were rarely reported as the ﬁrst-listed diagnosis (<1%).
Conclusion: VHD is a signiﬁcant cause of morbidity and mortality in the US. Mortality 
and hospitalizations for VHD have increased since 1980, especially in women and the 
elderly. The causes of these trends and implications for clinical and public health practice 
deserve further study.
7:27 a.m.
803-5 Long-Term Outcome of Asymptomatic Bicuspid Aortic 
Valve in the Community
Hector I. Michelena, Vuyisile T. Nkomo, Valerie A. Desjardins, A. Jamil Tajik, Maurice 
Enriquez-Sarano, Mayo Clinic, Rochester, MN
Background Congenital bicuspid aortic valve (BAV) is prevalent. Little is known about the 
outcome of patients with a normal or mildly dysfunctional BAV .
Methods Ninety three consecutive residents from Olmsted County, MN, diagnosed 
with BAV between1980-89 were identiﬁed who had ejection fraction(EF) >50%, aortic 
regurgitation grade ≤ 2/4, left ventricular end-diastolic dimension < 65mm, aortic valve 
peak Doppler velocity < 3.0 m/sec and mean Doppler gradient < 20 mmHg. An aortic 
valve degeneration point score (DS) was constructed based on leaﬂet doming (0-1) 
and degree of valve thickening (0-3), calciﬁcation (0-3) and mobility (0-3) at baseline 
echocardiogram (total score range 0 to10).
Results Age at diagnosis was 27±16 years and 70% were male. Baseline DS median 
was 1 (25-75% 0-2). During a follow-up of 16±5 years, there were 12 deaths. Aortic valve 
replacement (AVR) or valvotomy was needed in 22 patients; severe aortic stenosis was 
the reason in 15 (68%). Median age at AVR was 50 years (range 14-77). At 20 years 
follow-up, the rates of death, aortic valve surgery, cardiovascular (CV) events (cardiac 
death, stroke, heart failure, endocarditis or surgery) were respectively 19±5%, 29±6% 
and 39±7%. Determinants of CV events were age, EF (both p<0.001) and DS (p<0.01, 
RR 2.85[1.27-6.44] for score ≥2, Figure).
Conclusions In this community study of patients with BAV and no or minimal 
hemodynamic abnormality, long-term mortality is low but the incidence of CV events and 
AVR is high and is predicted by baseline DS.
7:39 a.m.
803-6 Bicuspid Aortic Valve Phenotype Predicts Aortic Elastic 
Properties
Benjamin M. Schaefer, Peter Byers, Mark Lewin, Karen Stout, Catherine M. Otto, 
University of Washington, Seattle, WA
Background: Bicuspid Aortic Valves (BAV) are associated with aortic dilation and 
dissection. We hypothesized that aortic elastic properties (distensibility and stiffness) differ 
between BAV patients with right-left (RL) and anterior-posterior (AP) leaﬂet orientation.
Methods: We studied 92 patients with BAV (18 RL, 74 AP). We excluded patients with 
age < 18, aortic dilation > 4.5 cm, poor echo quality or without hemodynamics. 12 patients 
with RL phenotype were matched for gender and valve function with AP phenotype 
controls. 2D echo aortic diameter (mm) was measured at end-diastole (Dd) and end-
systole (Ds). Cuff blood pressures were used for aortic systolic (Ps), diastolic (Pd) and 
pulse (PP) pressure. Distensibility and stiffness were compared between groups using 
standard statistics. Values are noted RL vs. AP as mean ± standard deviation or as 
median [range].
Results: There were no signiﬁcant differences in age, blood pressure, valve stenosis (jet 
velocity 247±86 vs.198±74 cm/s) or regurgitation, or diameters in ascending (30 [18-
43] vs. 29 [22-39]) or descending (15 [10-19] vs. 14 [10-17]) aorta. Arch diameter was 
signiﬁcantly different (27 [19-36] vs. 21[18-30], p=0.02). Elastic measures did not correlate 
with age (R2<0.1) or gender. Signiﬁcant differences in elastic properties are shown. 
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Conclusion: BAV phenotype may predict elastic properties of the aorta independent of 
gender, age or valve function. Further studies need to determine if RL phenotype is a risk 
for aortic dissection.
7:51 a.m.
803-7 Impact of Antiphospholipid Antibodies on 
Cardiovascular Disease in Systemic Lupus 
Erythematosus
Afshin Farzaneh-Far, Mary J. Roman, Michael D. Lockshin, Richard B. Devereux, 
Stephen A. Paget, Mary K. Crow, Adrienne Davis, Lisa Sammaritano, Daniel M. Levine, 
Jane E. Salmon, Weill Medical College of Cornell University, New York, NY, Hospital for 
Special Surgery, New York, NY
Background: Cardiovascular involvement in systemic lupus erythematosus (SLE) 
is common. The extent to which antiphospholipid antibodies (APLAs) inﬂuence SLE’s 
cardiovascular manifestations is either controversial or unreported. This study examined 
the association of APLAs with valvular, myocardial and arterial disease in SLE.
Methods: 200 SLE patients (43±13 years, 94% women) were recruited at scheduled 
outpatient visits. All patients underwent comprehensive interview, physical examination and 
measurement of APLAs. Echocardiography assessed left ventricular (LV) size and function, 
and carotid ultrasonography detected atherosclerosis and measured arterial stiffness.
Results: APLAs were positive in 33 patients (17%). Clinically evident coronary artery 
disease was equally prevalent in patients with and without APLAs (6 vs. 4%, p=0.57), 
whereas clinical cerebrovascular disease tended to be more common in the APLA patients 
(18 vs. 8%, p=0.09). Mitral valve nodules were more common in the APLA positive group 
(15% vs. 5%, p=0.03) as was the presence of moderate to severe mitral regurgitation 
(15% vs. 5%, p=0.03). Moreover, APLA IgG levels were higher in patients with mitral 
valve nodules than those without (47 U/mL vs. 11 U/mL, p=0.05). There was no signiﬁcant 
difference in the presence of aortic valve nodules (3% vs. 6%, p=0.50) or regurgitation 
(12% vs. 11%, p=0.86) between APLA positive and negative patients. LV dimensions, 
mass, ejection fraction, cardiac index and total peripheral resistance were similar in APLA 
positive and negative patients as were carotid stiffness and atherosclerosis (31 vs. 37%, 
p=0.57). Patients with APLAs were less likely to have used prednisone (78 vs. 93%, 
p=0.01) or azathioprine (17 vs. 36%, p=0.04).
Conclusions: Our study, the largest echocardiographic study to date in patients with 
SLE, indicates that APLAs are associated with mitral valve nodules and signiﬁcant mitral 
regurgitation but not with aortic valve abnormalities, atherosclerosis, arterial stiffness or 
left ventricular structure or function.
8:03 a.m.
803-8 A Prospective Randomized Trial of a Rapid Fibrinolytic 
Protocol for Left-sided Prosthetic Valve Thrombosis: 
Interim Analysis
Ganesan Karthikeyan, Navin Mathew, M. Kalaivani, Sandeep Singh, Ravi S. Math, Bhim 
Shankar, Rajvir Singh, All India Institute of Medical Sciences, New Delhi, India
Background: The optimal ﬁbrinolytic strategy for left sided prosthetic valve thrombosis 
(PVT) is not known. A large initial bolus dose of streptokinase (SK) might accelerate 
ﬁbrinolysis and restore valve function more rapidly.
Methods: This is an ongoing, prospective, randomized trial comparing 2 ﬁbrinolytic 
protocols in a ﬁrst episode of PVT. In the rapid ﬁbrinolytic protocol (RFP) 1.5 MU of 
SK was given over 1 hour, followed if required by a 0.1 MU/h infusion. In the standard 
protocol (SP) 0.25 MU was given over 30 minutes, followed by an infusion of 0.1 MU/h. 
Serial echocardiography and ﬂuoroscopy were done to monitor therapy. The primary end 
point was the occurrence of a complete clinical response (CCR, complete hemodynamic 
response without any major complication). 58 patients are required in each arm for 
detecting a 30% difference with 80% power at �=0.05. The Mann-Whitney rank sum test 
and logistic regression analysis were used to analyze differences in treatment outcome 
and detect associations between variables and outcomes.
Results: Between Nov 04 and Aug 05, we randomized 40 consecutive patients 
(20 RFP, 20 SP). Patients assigned to the RFP were signiﬁcantly more likely to have 
a CCR (p=0.047), with no increase in adverse events.(Table) Better NYHA class (RR 
10.2, p=0.004) and assignment to the RFP (RR 4, p=0.05) were the only predictors of a 
complete response. 
RR 95% CI P value
Primary end point (Complete clinical response) 4.0 0.98-16.27 0.053
ADVERSE OUTCOMES
Incomplete response 0.17 0.03-0.92 0.04
Death 2.1 0.18-25.3 0.56
Major bleeding 1.0 0.13-7.91 1.0
Death or major bleeding 0.63 0.09-4.2 0.64
Minor bleeding 2.43 0.51-11.5 0.26
Fever 0.14 0.03-0.65 0.01
SK INFUSION
Duration of infusion ≤12 hrs 12.0 2.7-53.3 0.001
Dose of SK > 3 MU 7.43 1.78-31.0 0.006
Conclusions: In this interim analysis, the RFP appears to be more efﬁcacious than the 
SP, for treatment of a ﬁrst episode of PVT.
8:15 a.m.
803-9 Factors Associated With Development of Signiﬁcant 
Tricuspid Regurgitation Late After Successful Left-
sided Valve Surgery
Mi-Jeong Kim, Il-Woo Suh, Young-Hoon Jeong, Chang-Bum Park, Se-Whan Lee, Jong-
Min Song, Duk-Hyun Kang, Hyun Song, Jae Won Lee, Meong Gun Song, Jae-Kwan 
Song, Asan Medical Center, Seoul, South Korea
Background: Despite sporadic case reports of development of signiﬁcant tricuspid 
regurgitation (TR) late after successful left-sided valve surgery, the incidence and factors 
associated with late TR development have not been seriously investigated.
Methods: Preoperative echocardiography of patients who underwent mitral and/or aortic 
valve surgery from 1995 to 2000 was reviewed. Patients with signiﬁcant TR (grade ≥3/4) or 
organic tricuspid valve (TV) abnormality were excluded. Using follow-up echocardiography 
(74.1± 26.9 months after surgery), the severity of TR was graded (1+ through 4+) based 
on spatial distribution of distal TR jet in color Doppler. Development of late signiﬁcant TR 
was deﬁned as increase of TR by ≥2 grade compared with preoperative ﬁndings.
Results: A total of 654 patients was enrolled and among them 54 patients (9.0%) showed 
development of late signiﬁcant TR. Patients who underwent both mitral and aortic valve 
surgery showed signiﬁcantly higher incidence (ﬁgure, left). Old age, atrial ﬁbrillation, 
rheumatic etiology and female gender were independent factors associated with late 
signiﬁcant TR. The 5-year event-free survival rate was signiﬁcantly lower in patients with 
late TR (90.7± 2.5% versus 84.0±10.4%, p=0.02).
Conclusions: Rheumatic valvular heart disease without deﬁnite evidence of direct TV 
involvement is a risk factor of late TR development, and special consideration on timing of 
surgery for these patients with high risk factors seems to be necessary.
POSTER SESSION
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Monday, March 13, 2006, 9:00 a.m.-12:30 p.m.
Georgia World Congress Center, Hall B1
Presentation Hour: 11:00 a.m.-Noon
962-19 Ischemic Mitral Regurgitation Is an Independent 
Predictor of Heart Failure and Death in Survivors of 
Myocardial Infarction: A Prospective Study
Doron Aronson, Robert Tzuckerman, Noa Goldsher, Diab Mutlak, Jonathan Lassik, Haim 
Hammerman, Shimon Reisner, Yoram Agmon, Rambam Medical Center, Haifa, Israel
Background: Ischemic mitral regurgitation (IMR) has been associated with poor outcome 
after myocardial infarction (MI). IMR may promote the development of heart failure (HF). 
However, little data is available on the relationship between IMR and the risk for long-term 
development of HF.
Methods: We prospectively studied 895 patients (pts) without previous HF who were 
admitted with MI, and discharged from hospital in stable condition. Echocardiography was 
performed within 7 ± 3 days from admission. IMR was classiﬁed into 3 groups: 1) none 
or trivial, 2) mild, 3) moderate or severe. The primary endpoints were ﬁrst re-admission 
for HF and all-cause mortality. The relation of IMR severity to the primary endpoints 
was evaluated using a Cox model, adjusting for age, sex, diabetes, hypertension, prior 
infarction, Killip class on admission, ST-elevation MI, anterior MI, reperfusion therapy, and 
pre-discharge ejection fraction (EF). Recurrent infarction was included in the model as a 
time-dependent covariate.
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Results: Mild IMR was present in 40% and moderate or severe IMR in 6% of cases. 
During a median follow up of 28 months (range, 12 to 48), 115 pts were admitted for HF 
and 109 pts died. Compared to pts with no/trivial IMR, the adjusted RR for HF was 2.6 
(95% conﬁdence interval (CI) 1.7-4.2; P < 0.0001) in patients with mild IMR and 4.0 (95% 
CI 2.2-7.4; P < 0.0001) in pts with moderate/severe IMR.
Mild IMR was not a signiﬁcant predictor of mortality (adjusted RR 1.2, 95% CI 0.8-1.9; P = 0.4). 
However, moderate/severe IMR was associated with an adjusted RR of 2.7 for mortality (95% 
CI 1.5-4.8; P = 0.001). HF before death occurred in 19.4% of patients without IMR, 40.7% in 
patients with mild IMR, and in 57.9% of pts with moderate/severe IMR (P < 0.0001).
Conclusion: IMR is a strong independent predictor of long-term HF and death in 
survivors of MI. Even mild IMR is associated with a substantial increase in the risk for HF, 
and death is frequently preceded by HF in pts with IMR.
962-20 Is Myxomatous Mitral Valve Disease the Leading Cause 
of Partially Flail Mitral Valve Leaﬂet and Ruptured 
Chordae?
Salim Adawi, Sigal Aviram, Basil S. Lewis, Avinoam Shiran, Lady Davis Carmel Medical 
Center, Haifa, Israel, Technion, Israel Institute of Technology, Haifa, Israel
Background: Ruptured chordae leading to partially ﬂail mitral valve (MV) leaﬂet and mitral 
regurgitation (MR) is considered to be caused primarily by myxomatous MV disease. The 
aim of this study was to determine the prevalence of non-myxomatous partially ﬂail MV 
and ruptured chordae and characterize this group of pts.
Methods: We identiﬁed 73 pts in the echo database with partially ﬂail mitral valve, of 
whom 64 pts (88%) had clearly identiﬁable ruptured chordae. Pts were classiﬁed as 
myxomatous or non-myxomatous based on MV leaﬂet anatomy (leaﬂet redundancy) 
using transthoracic (59 pts) or transesophageal (14 pts) echocardiography.
Results: Myxomatous MV disease was present in 18 pts (25%), 44 pts (60%) had a non-
myxomatous MV, and 11 pts (15%) were indeterminate. Compared to pts with myxomatous 
MV, pts with non-myxomatous MV were signiﬁcantly older, and had more mitral annulus 
calciﬁcation (MAC), aortic sclerosis, and papillary muscle sclerosis (Table). MR severity, 
MV segment involved, and chamber size were similar. There was no signiﬁcant difference 
in symptoms of heart failure or functional class, but pts with non-myxomatous MV were 
more likely to have symptoms for ≤1 month.
Conclusions: In our population of patients with ruptured chordae and partially ﬂail MV, 
most patients had a non-myxomatous etiology (m/p wear and tear), which was associated 
with older age, degenerative changes such as MAC and aortic sclerosis, and short term 
symptoms.
Myxomatous MV 
(n=18)
Non-myxomatous MV 
(n=44) p value
Age (y) 62+12 77+9 <0.0001
Sex (M) 16/18 (89%) 32/44 (73%) 0.3
Severe MR 18/18 (100%) 39/44 (89%) 0.3
EF (%) 68+4 60+13 0.002
MV leaﬂet thickness 
(mm) 3.9+1.3 2.7+0.7 0.001
MAC 3/18 (17%) 23/44 (52%) 0.02
Aortic sclerosis 1/18 (6%) 24/44 (55%) 0.001
Papillary muscles 
sclerosis 1/18 (6%) 16/44 (36%) 0.03
Symptoms <1 month 1/9 (11%) 16/22 (73%) 0.006
 
962-21 Survival After Coronary Revascularization, With and 
Without Mitral Valve Repair, in Patients With Ischemic 
Mitral Regurgitation. Importance of Pre-operative 
Myocardial Viability
Jean-Benoît le Polain de Waroux, Anne-Catherine Pouleur, Belge Benedicte, Agnès 
Pasquet, Bernhard L. Gerber, Philippe Noirhomme, Gebrine El Khoury, Vanoverschelde 
Jean-Louis, Cliniques Universitaires St Luc, Brussels, Belgium
Background: The impact of adding mitral valve repair (MVR) to coronary bypass grafting 
(CABG) in patients (pts) with ischemic mitral regurgitation (iMR) is unclear. This study 
aimed at comparing the 30-day and 5-year survival of pts with iMR undergoing CABG 
or CABG+MVR and to investigate the role of myocardial viability (VM) in the prognostic 
response to MVR.
Methods: We studied 76 coronary pts (61 men, 62±9 yrs) with poor LVEF (37± 10%) and 
≥ 2 iMR who underwent low-dose dobutamine echo to identify VM before CABG. Survival 
of 34 pts undergoing CABG+MVR (restrictive annuloplasty) was compared to that of 
the 42 pts who underwent CABG alone. Groups were further substratiﬁed according to 
preoperative VM.
Results: At baseline, all groups were similar. During follow-up, 30 pts (39%) died. 30-
day survival tended to be lower in CABG+MVR (83%) than in CABG (96%, p=0.06), 
irrespective of VM. 5-yr survival was better in pts with VM, irrespective of MVR, (76+10%) 
than in those without VM, whether undergoing CABG (56±9%) or CABG+MVR (35±11%, 
p<0.01 vs VM). At 1 yr, residual iMR was lower in CABG+MVR+VM pts (1.2±0.9) than 
in the other groups (CABG+MVR nonviable: 1.6±0.5; CABG viable: 1.8±0.5; CABG 
nonviable: 2.0±0.9, p<0.05). iMR ≥2 was also less frequent in CABG+MVR+VM pts (33%) 
than in the other groups (64, 78 and 68%, respectively).
Conclusions: In pts with iMR, survival after CABG is inﬂuenced by the presence of VM. 
By contrast, adding MVR to CABG does not affect survival except in pts without VM in 
whom it increases early mortality.
962-22 Geometric Determinants of Chronic Ischemic Mitral 
Regurgitation in Patients With Inferior Myocardial 
Infarction: Three-Dimensional Magnetic Resonance 
Imaging Study
Shuichiro Kaji, Atsushi Yamamuro, Koichi Tamita, Makoto Kinoshita, Tomoko Tani, 
Kunihiko Nagai, Kazuaki Tanabe, Yasuki Kihara, Kobe General Hospital, Kobe, Japan
Background: Previous animal study demonstrated that lateral displacement of the posterior 
papillary muscle (PPM) is crucial in the pathogenesis of chronic ischemic mitral regurgitation 
(CIMR). However, the three-dimensional (3D) distortions of the mitral apparatus including 
both papillary muscles (PM) in patients with CIMR were not precisely investigated. The 
purpose of this study was to clarify the 3D determinants of CIMR in patients with prior 
myocardial infarction (MI) using cardiac magnetic resonance imaging (MRI).
Methods: We used the whole-heart MRI technique to evaluate the geometry of the mitral 
apparatus that provides 3D visualization of the entire heart using a navigator respiratory 
gating technique with a high spatial resolution (reconstructed voxel size = 1.1x1.8x1.3 
mm3). End-systolic whole-heart MR images were acquired in 35 patients with inferior 
MI. The mitral annular dimensions and 3 components (lateral, posterior, apical) of PM 
positions (tip and base) to the centroid of mitral annulus were calculated. CIMR was 
graded as none (0), trace (0.5), mild (1), moderate (2), moderate-severe (2.5) or severe 
(3) using color-Doppler echocardiography. Hence, the patients were grouped by CIMR 
grades (≥2+, n=13 versus ≤1+, n=22).
Results: The septal-lateral mitral annular diameter was signiﬁcantly greater in CIMR(+) 
patients than CIMR(-) (34±4 versus 29±4mm, p<0.001). Both PPM tips and bases were 
displaced more laterally in CIMR(+) patients (11±4 versus 4±4mm, p<0.001; 19±6 
versus 10±4mm, p<0.001; respectively). The lateral component of the PPM tethering 
length (mid-septal annulus to PPM) was signiﬁcantly longer in CIMR(+) patients (26±5 
versus 17±4mm, p<0.001), whereas the posterior and apical components did not show 
signiﬁcant differences. Multiple regression analysis identiﬁed the lateral component of the 
PPM tethering length as the strongest predictor of the CIMR grade (r=0.70, p<0.001).
Conclusion: The lateral component of the PPM tethering length is the primary 
determinant of CIMR in patients with inferior MI.
962-23 Myocardial Strain Predicts Left Ventricular Responses 
to Valve Surgery in Asymptomatic Severe Mitral 
Regurgitation
Lizelle Hanekom, Sudhir Wahi, Rodel Leano, Brian Haluska, Chris Smith, Thomas H. 
Marwick, University of Queensland, Brisbane, Australia
Background:We sought the value of strain rate imaging (SRI) for the prediction of left 
ventricular (LV) dysfunction in asymptomatic severe mitral regurgitation (MR).
Methods: Exercise echo and SRI were performed in 31 MR pts (60±13y, 14 female, EF 
62±5%) at baseline and after MV surgery. 18 pts had myocardial biopsy performed at 
surgery for evaluation of ﬁbrosis. Long axis end systolic strain and peak systolic strain 
rate by SRI (ESS and SR) and 2D strain (2D-ESS 2D-SR) were averaged per patient at 
baseline and on follow-up echo. ROC curve analysis were performed to assess optimal 
cut-off points for SRI parameters in the prediction of LV deterioration post-operatively.
Results: Of the 31 pts studied, 39% had deterioration of LV function on follow-up echo 
(mean deterioration -8±6%, 8±5 m post-surgery). MR pts with deterioration in LV function 
had signiﬁcantly lower baseline SR, ESS, 2D-SR and 2D-ESS (Table). By applying the 
optimal cut-offs obtained from ROC analysis, 2D-SR<-0.9 and 2D-ESS<-14% predicted 
myocardial deterioration post-operatively with a sensitivity and speciﬁcity of 82/95% 
and 82/85% respectively. Myocardial ﬁbrosis was present in 5 pts and absent in 13 pts. 
Fibrosis+ pts had signiﬁcantly lower SR (-0.82±0.03/s vs. -1.3±0.2/s, p<0.0001), ESS 
(-10.2±1% vs. -18.1±3%, p<0.001), 2D-SR (-0.6±0.07/s vs. -1.17±0.2/s, p<0.0001) and 
2D-ESS (-11.6±2% vs. -17±3%, p<0.001) compared with ﬁbrosis- pts. 
Conclusions: Myocardial strain is predictive of LV recovery after MV surgery.
Signiﬁcance compared between patients with LV deterioration and LV 
preservation.
SRI parameters Baseline SR (/s)
Baseline ESS 
(%)
Baseline 2D-
SR (/s)
Baseline 2D-
ESS (%)
LV deterioration 
(12) -0.95 (0.3)* -12.8 (4)* -0.86 (0.3)** -12 (2)**
LV preservation 
(19) -1.36 (0.3) -18.5 (4) -1.23 (0.2) -17.7 (3)
AUC 0.85 0.85 0.9 0.93
Optimal cut-off -1.2 -16 -0.9 -14
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962-24 Clinical Presentation and Management of Patients With 
Severe Mitral Regurgitation: Are There Differences 
Between Men and Women?
Agnes Cachier, Bernard Iung, David Messika-Zeitoun, Pilar Tornos, Dominique Himbert, 
Eric Butchart, Gabriel Baron, Alec Vahanian, Bichat Hospital, Paris, France
Background: It is not known whether clinical presentation and management of patients 
with severe mitral regurgitation (MR) differs according to gender. We used the data of the 
Euro Heart Survey on valvular heart disease, in order to compare patient characteristics 
and decision for surgery in men and women with severe MR.
Methods: Between April and July 2001, 5001 patients were included in the Euro Heart 
Survey; 877 had MR, among whom 546 had severe MR, deﬁned as MR ≥ grade 3/4.
Results: Characteristics of men and women with severe MR are compared in the Table. 
Of the 155 patiens who had undergone surgery during the study period, valve repair was 
performed in 37% of the women and 53% of the men (p=0.04). Thirty-day mortality was 
6.6% in women and 2.2% in men (p=0.17). One-year survival was 97±1% in women and 
94±2% in men (p=0.40).
Conclusions: Signiﬁcant differences exist between men and women with severe MR 1) 
Women are referred at a more advanced clinical stage than men, although LV function 
does not differ. 2) Overall, decision for surgery does not differ according to gender. 
However, a decision to operate was taken less frequently in women with few or no 
symptoms. 3) In women, valve repair is less frequently performed and operative mortality 
tends to be higher than in men.
Comparison of men and women with severe MR
Women
(n=254)
Men
(n=292) p
Age (years) 67±14 64±14 0.07
NYHA class III-IV (%) 56 44 0.005
Atrial ﬁbrillation (%) 38 25 0.001
Left ventricular ejection fraction 0.54±0.14 0.52±0.16 0.10
Indexed left ventricular end-systolic dimension (mm) 22±5 22±5 0.47
Coronary disease (%) 35 50 0.01
Decision to operate (all patients) (%) 42 48 0.17
Decision to operate (NYHA I-II) (%) 32 48 0.01
Decision to operate (NYHA III-IV) (%) 50 48 0.80
962-25 Effect of Angiotensin Blockade on the  
Degree of Organic Mitral Regurgitation:  
A Randomized Clinical Trial
Maurice Enriquez-Sarano, David Messika-Zeitoun, Delphine Detaint, Jean-Francois 
Avierinos, Vuyisile T. Nkomo, Jamil A. Tajik, Mayo Clinic, Rochester, MN
Background: Mitral regurgitation (MR) has serious prognostic implications related to 
its degree. There is no established medical treatment proven to reduce the degree and 
consequences of organic MR. Therefore, we tested in a randomized clinical trial the effect 
of Angiotensin-blockade in patients with organic MR.
Methods: The degree of MR was measured by Doppler-Echocardiography as the 
regurgitant volume (RVol) using 3 methods (Quantitative Doppler, Quantitative 2D, PISA) 
which were averaged in 135 patients with organic MR of at least moderate degree (RVol 
≥30 mL/beat). The patients were then randomly assigned to oral administration of placebo 
(n=44) or Ramipril (n=47) 20 mg daily or Candesartan (n=44) 32 mg daily for 1 year 
and RVol was remeasured at trial end. Left atrial volume (LAVol) was also measured at 
baseline and at trial end.
Results: At baseline compared to the placebo group, in the Candesartan and Ramipril 
group there was no difference in age (67.5±15 vs.64.4±15 and 64±13 years, p=0.44), 
female sex (36 vs. 39 and 36%, p=0.96), systolic blood pressure (138±18 vs. 135±19 
and 135±14 mmHg, p=0.71), atrial ﬁbrillation (11 vs. 7 and 11%, p=0.74), RVol (63±22 
vs. 65±23 and 65±23 mL/beat, p=0.87) and LAVol (137±56 vs. 128±45 and 129±47 mL, 
p=0.87). After 1 year the systolic blood pressure was higher in the placebo group (135±14 
vs. 121±19 and 122±16 mmHg, p<0.001). The 1-year RVol differences between groups 
did not reach statistical signiﬁcance (68±24 vs. 62±23 and 62±22 mL/beat, p=0.46) 
but paired analysis showed progression in the placebo group (+5.7±7.1 mL, p<0.001) 
vs. regression in the Candesartan (-3.3±7.5 mL, p=0.006) and Ramipril (-3.5±9.6 mL, 
p=0.02) groups, which were highly different (p<0.001). Similarly, with placebo, LAVol was 
higher at 1 year (154±62 vs. 122±41 and 124±45 mL, p<0.006) and progressed more 
(+16.5±23 vs. -7±17 and -3±10 mL, p<0.001).
Conclusions: Angiotensin blockade by Candesartan or Ramipril at maximum tolerated 
dose in patients with organic MR moderate or severe, results over 1 year in stabilization of 
the MR degree and LA consequences compared to the progression observed placebo.
962-26 Preoperative Exercise Capacity Predicts Survival 
and Persistent Symptoms After Surgery for Chronic 
Nonischemic Mitral Regurgitation
Phyllis G. Supino, Jeffrey S. Borer, Clare Hochreiter, Edmund McM Herrold, Jacek J. 
Preibisz, Paul Kligﬁeld, Weill Medical College of Cornell University, New York City, NY
Background: Preoperative (preop) exercise duration (ex dur) predicts long-term outcome 
after valve surgery (VS) among symptomatic patients with aortic regurgitation. However, 
the prognostic value of ex dur in patients who undergo VS for nonischemic mitral 
regurgitation (MR) is undeﬁned.
Methods: Therefore, among 40 patients (20 male, age at VS: 56±12 years; Functional Class 
[FC]: 2.1±0.9) who had MVS for chronic severe MR, we tested the hypothesis that preop ex 
dur (modiﬁed Bruce protocol) predicts: (1) long-term postoperative survival and (2) persistence 
of FC ≥2 symptoms ≤2 years after MVS. No patient had other important valve disease; 3 
had clinically unsuspected associated coronary artery disease, including 2 who underwent 
MVS+coronary bypass. Exercise was stopped in 92% of patients due to fatigue±dyspnea.
Results: During average follow-up of 8±3 years, 7/40 (17.5%) patients died: sudden (3), 
congestive heart failure (1), myocardial infarction (1, without coronary artery disease at 
MVS]), documented noncardiac cause (2); 4 patients (including 3 who died) had persistent 
FC≥2 symptoms ≤2 years after VS. Preop ex dur predicted all cause postoperative death 
(p<.05). Among patients who exercised ≤7 minutes (upper bound of the lower tercile 
of preop ex dur), risk of postoperative death was 5 times greater (Average Annual 
Risk=4.9% ) than in patients who exercised > 7 minutes (Average Annual Risk=0.91%, 
p<.02 [all patients]; p=.03 [no preop coronary artery disease]). Preop ex dur also predicted 
FC≥2 symptoms ≤2 years after VS (p<.04 [all patients], p=.03 [no preop coronary artery 
disease]). Neither age, gender, rheumatic etiology, preop cardiac drugs nor preop FC was 
associated with either outcome (NS, all variables).
Conclusions: Preop ex dur is directly associated with outcome after MVS among 
patients with non-ischemic MR and predicts survival and symptom persistence better 
than commonly documented clinical variables. Thus, MVS is indicated not only in patients 
reporting symptoms but in those with markedly subnormal ex dur even if symptoms are 
not reported; perhaps more importantly, consideration and testing of adjunctive strategies 
to improve post MVS outcome in this group is appropriate.
962-27 Functional Mitral Stenosis Following Surgical 
Annuloplasty for Ischemic Mitral Regurgitation
Kayoko Kubota, Yutaka Otsuji, Tetsuya Ueno, Yuko Maki, Takayuki Ueno, Eiji Kuwahara, 
Naoko Mizukami, Masaaki Miyata, Shuichi Hamasaki, Akira Kisanuki, Shinichi Minagoe, 
Robert A Levine, Ryuzo Sakata, Chuwa Tei, Kagoshima University, Kagoshima, Japan
Background: Mitral leaﬂets are tethered even in diastole with limited valve opening and 
abnormal ﬁlling ﬂow direction (Figure) in patients with ischemic mitral regurgitation (MR). 
We hypothesisized that surgical annuloplasty to reduce annular size may occasionally 
result in functional mitral stenosis (MS) in patients with ischemic MR.
Methods: In 29 patients with annuloplasty for ischemic MR, 17 with annuloplasty for non-
ischemic MR, and 10 normal subjects, diastolic mitral valve area (MVA) was obtained ( 
MVA x Velocity Time Integral of mitral ﬁlling ﬂow = LV ﬁlling volume = LVEDV - LVESV). 
Variables of diastolic leaﬂet tethering, angle of mitral ﬁlling ﬂow relative to the annulus, 
and annular were also measured (Figure).
Results: 1) MVA and annular area were signiﬁcantly reduced in patients with ischemic 
etiology compared to non-ischemic etiology or normal subjects (MVA: 1.6±0.2 vs. 2.3±0.3 
vs. 4.7±0.3 cm2, p<0.01) (annular area: 3.3±0.5 vs. 3.9±0.5 vs. 5.1±0.4 cm2, p<0.01) with 
signiﬁcantly different incidence of MVA<1.5cm2 (8/29 vs. 0/17 vs. 0/10, p<0.01). 2) Diastolic 
tethering variables were also signiﬁcantly reduced in patients with ischemic etiology (α1: 
65±9 vs. 76±9 vs. 79±3 degree, p<0.01) (α2: 87±14 vs.98±12 vs. 96±7 degree, p=0.01) 
(β: 59±8 vs. 78±5 vs. 84±3 degree, p<0.01).
Conclusions: Surgical annuloplasty for ischemic MR occasionally results in mild to 
moderate functional MS with diastolic leaﬂet tethering and abnormal ﬁlling ﬂow direction.
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984-19 Impact of Chronic, Daily Antiplatelet Therapy on 
Embolic Events in Infective Endocarditis
Nandan S. Anavekar, Imad Tleyjeh, Nagesh S. Anavekar, Zaur Mirzoyev, Christopher 
Haddad, Masud Khandaker, Jamil Tajik, Walter Wilson, James Steckelberg, 
Krishnaswamy Chandrasekaran, Larry M. Baddour, Mayo Clinic, Rochester, MN, 
University of Melbourne, Melbourne, Australia
Background: Risk of embolism in infective endocarditis (IE) is related to vegetation 
size which is dependent on platelet function. Whether chronic, daily antiplatelet therapy 
(that is prescribed for non-infectious reasons) reduces the risk of embolism in those who 
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subsequently develop infective endocarditis has not been formally addressed.
Methods: A retrospective study of adult patients with a diagnosis of IE, who presented 
to the Mayo Clinic, Rochester, between 1980-1998. The cohort was divided into 2 groups 
based on whether or not they had received chronic, daily antiplatelet therapy over the 
prior 6 months before IE diagnosis. Anti-platelet therapy included aspirin, dipyridamole, 
clopidogrel, ticlopidine or any of their combinations. The primary endpoint was a the ﬁrst 
in-hospital embolic event following IE diagnosis. Multivariable logistic regression was 
used to assess the impact, if any, of chronic, daily antiplatelet therapy on risk of embolic 
events due to IE.
Results: One hundred and forty-seven (24.5%) of 600 patients suffered at least one 
embolic event and the most common (48.2%) embolic manifestation was stroke. Prior 
chronic, daily antiplatelet therapy was associated with a reduced risk of embolic events 
(12.0% versus 27.8%; p<0.001). Following adjustment for several co-variates known to 
inﬂuence both risk of embolism and propensity for antiplatelet use, the adjusted odds ratio 
for a single embolic event was 0.36 (95% CI 0.19, 0.68; p = 0.002 ) in favor of chronic, 
daily antiplatelet therapy use before diagnosis of IE.
Conclusions: These ﬁndings suggest that there may be a striking reduction in risk of 
emboli in patients who are receiving chronic, daily antiplatelet therapy for reasons other 
than infection and who subsequently develop IE. Based on ﬁndings from our investigation 
and on those of previous work in humans, the beneﬁts and risks of antiplatelet agents as 
adjunctive therapy of IE may vary dependent on time of initiation of antiplatelet treatment 
in relation to infection onset.
984-20 Elevation of Cardiac Troponin T in Infective Endocarditis 
Predicts an Adverse Outcome
Dylmitr Rittoo, Arrowe Park Hospital, Wirral, United Kingdom
Background: The prognostic signiﬁcance of cardiac Troponins in acute coronary 
syndromes is well established. The aim of this study was to determine whether elevation 
of serum cardiac Troponin T (cTnT) in patients with infective endocarditis would inﬂuence 
outcome.
Methods: Forty one patients satisfying the Duke criteria for infective endocarditis were 
studied prospectively. Patients received standard care including serial imaging with 
transthoracic and transoesophageal echocardiography. Serum cTnT was measured at 
the time of diagnosis and during the course of antibiotic therapy. The main outcome 
measures were death , stroke and emergency cardiac surgery.
Results: Serum cTnT was ≥ 0.10 µg/L in 21 patients (Group A) and < 0.01 µg/L in 20 
patients (Group B).
Group A: Median serum cTnT was 0.30 µg/L with a maximum of 2.67 µg/L. Vegetations 
were located on the aortic valve (n=9), mitral valve (n=6), both mitral and aortic valves 
(n=2), aortic valve prosthesis (n=3) and right atrium (n=1). Infecting organisms were 
streptococci species (n=6), staphylococci (n=9), and enterococci (n=3). Blood cutures 
were negative in 3 patients. Eight patients died . Ten patients had strokes.Two patients 
required emergency valve surgery.
Group B: Vegetations were on the aortic valve (n=9), mitral valve (n=1), mitral and 
aortic valves (n=1), aortic valve prosthesis (n=2), tricuspid valve (n=3), pacing leads 
(n=3) and pulmonary valve (n=1). Infecting organisms were streptococci species (n=7), 
staphylococci (n=7), enterococci (n=3), and others (n=2). Blood cultures were negative in 
1 patient. There was no death in this group. Two patients had strokes. One patient required 
emergency mitral valve surgery.
There was no signiﬁcant difference between the 2 groups with respect to age (65 ±16 vs 
63 ± 16 yrs), CRP (134 ± 78 vs 121 ±86 mg/L), serum creatinine (199 ± 206 vs 104 ±118 
µmol/L), left ventricular function, presence of cardiac failure or types of organisms. All the 
deaths and most of the strokes occurred in group A ( P=0.003).
Conclusions: Serum cardiac Troponin T is frequently elevated in infective endocarditis, 
especially when left sided valves are involved. It is a predictor of an increased risk of 
death and stroke.
984-21 Prospective Determination of the Prevalence of 
Clinically Unapparent Cerebral Embolization in Patients 
With Left-Sided Infective Endocarditis
Elissa C. Thompson, Steven Goldstein, Anthon Fuisz, Alexander Mark, Robert Laureno, 
Mark Lin, Howard A. Cooper, Washington Hospital Center, Washington, DC
Background: Cerebral embolization (CE) is a common complication of left-sided infective 
endocarditis (IE) and frequently impacts decisions regarding cardiac surgical intervention. 
The prevalence of clinically unapparent CE in patients with IE is unknown.
Methods: We prospectively enrolled 23 consecutive patients with deﬁnite IE by Duke 
criteria involving the aortic and/or mitral valve. An experienced study neurologist performed 
a complete history and neurological exam, and patients were categorized as having or 
not having clinical evidence of CE (stroke or TIA). Non-contrast brain MRI was performed 
on all patients and was interpreted by a single neuroradiologist who was blinded to the 
clinical history. MRIs were categorized with regard to the presence or absence of acute 
brain infarction (ABI).
Results: Baseline characteristics are presented in the Table. Of the 23 patients, 10 (43%) 
had clinical evidence of CE. All patients with clinical CE had at least one ABI on MRI. 
Among those without clinical CE, 5 (38%) had at least one ABI on brain MRI Among 
these 5 patients, multiple ABIs were common (mean 3.4, range 1-8). The mean size of the 
largest ABI in each asymptomatic patient was 11mm (range 3-28mm).
Conclusion: Clinically unapparent ABI, including large and multiple ABIs, appears to 
be common in patients with left-sided IE. Routine brain MRI imaging of all patients with 
left-sided IE may be indicated. 
Table 1
Age (mean) 58.7
Male/Female 14/9
White/Non-white 7/16
Hemodialysis Dependent 10
Affected Valve:
Mitral 5
Aortic 8
Both 10
Organism:
Methicillin Sensitive S. aureus 7
Methicillin Resistant S. aureus 5
Coagulase negative staphylococcus 2
S. viridans 1
Enterococcus 3
Fungal 1
Other or unknown 4
984-22 Echocardiographic Risk-stratiﬁcation for Early Surgery 
in Patients With Endocarditis Is a Cost-Attractive 
Alternative to Standard Care
Lawrence Liao, David F. Kong, Zainab Samad, Paul A. Pappas, James G. Jollis, Shu 
S. Lin, Andrew Wang, Vance G. Fowler, Jr., Vivian Chu, Daniel J. Sexton, G. R. Corey, 
Christopher H. Cabell, Duke Clinical Research Institute, Durham, NC
Background: Despite widespread acceptance of echocardiography for diagnosis of 
infective endocarditis (IE), few have evaluated its utility for identifying patients who need 
early surgical intervention to prevent stroke.
Methods: We constructed a decision tree and Markov analysis model using published 
and institutional data to estimate the cost-effectiveness of an echocardiographic risk-
stratiﬁcation strategy for valve surgery with IE. The models compared medical therapy 
alone, surgery for high-risk patients based on clinical factors (“standard care”), and 
surgery for high risk patients based on echocardiographic ﬁndings (“echocardiography-
guided strategy” (EGS)). Long term costs were discounted in the base case scenario at 
3% annually and standardized to 2003 dollars using the medical care component of the 
Consumer Price Index.
Results: The cost per patient for medicine alone, standard care and EGS was $46,914, 
$52,961 and $57,157, respectively. The expected quality-adjusted life years (QALY) for 
medicine alone, standard care, and EGS were 4.93 years, 5.08 years, and 5.45 years, 
respectively. Compared to medicine alone, standard care cost $40,420 per QALY saved 
and the EGS cost $19,632 per QALY saved. Compared to standard care, the EGS 
cost $11,276 per QALY saved. In sensitivity analyses, the incremental cost of the EGS 
compared to the standard care strategy remained < $50,000/QALY across a broad range 
of scenarios. In the sensitivity analyses, the variable with the greatest effect on cost-
effectiveness was the baseline risk for stroke. For populations with stroke risk less than 
14%, the EGS was not cost-attractive (ICER >$50,000/QALY). At stroke risk between 
14% and 32%, the ICER for the EGS was attractive (< $50,000/QALY). The EGS became 
economically dominant (costing less for greater effectiveness) at any baseline stroke risk 
greater than 32%.
Conclusions: Echo-guided risk stratiﬁcation for surgery is a cost-attractive treatment 
strategy for IE, as it improves outcome for an incremental cost < $50,000/QALY. The EGS 
remains economically attractive across a broad range of assumptions.
984-23 Intravenous Heroin Increases the Risk of Right-sided 
Infective Endocarditis Compared to Other Intravenous 
Drugs of Abuse
Lisa G. Winston, Meei-Horng Yang, Gabriela Kovacicova-Lezcano, Leah Schrinel Juhle, 
Ann F. Bolger, University of California, San Francisco, San Francisco, CA, San Francisco 
General Hospital, San Francisco, CA
Background: Injection drug users (IDUs) are at risk for infective endocarditis (IE), 
especially tricuspid valve (TV) IE. Limited data suggest that IDUs are more likely to 
have TV and mitral valve (MV) thickening compared with non-IDUs. Commonly injected 
substances have very different hemodynamic impacts; whether the type of drug injected 
affects speciﬁc valve involvement has received little study.
Methods: From 1996-2003, all records from San Francisco General Hospital were 
searched for ICD9 codes pertaining to IE. 247 discrete IE episodes in 238 patients were 
analyzed. IDU status was obtained by structured chart review, including history, toxicology 
results, and methadone use. Statistical analyses were performed using STATA 8.0.
Results: 184 of 247 IE episodes occurred in IDUs. Among IDUs, 67 episodes occurred 
in heroin-only users, 78 in users of heroin plus cocaine and/or methamphetamine, 24 in 
users of cocaine and/or methamphetamine but not heroin, and 15 had no speciﬁc drug 
information recorded. IDU overall was signiﬁcantly associated with TV vegetation seen 
on echocardiography (O.R.=5.3, p<0.001). Among IDUs, any use of heroin increased the 
likelihood of TV involvement compared to heroin non-use (O.R.=3.9, P=0.03). Heroin-only 
users were more likely to have a TV vegetation compared with users of only cocaine and/
or methamphetamine (O.R.=3.7, P=0.05). Users of cocaine and/or methamphetamine 
without heroin were not statistically more likely than non-IDUs to have TV involvement 
(O.R.=1.7, P=0.8).
Conclusions: Among IDUs, heroin was associated with increased risk for TV IE compared 
with other drugs. Heroin use may create more TV damage and insufﬁciency, increasing TV 
vulnerability to IE. In addition, the mechanism may relate to acute elevation of pulmonary 
arterial pressures during heroin-induced respiratory depression, leading to increased TV 
regurgitation severity and velocities. Cocaine and methamphetamine may be associated 
with more acute and chronic left-sided valvular insufﬁciency due to elevated systemic 
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afterload. These ﬁndings may help to explain differences in the frequency of right-sided IE 
reported from different regions with variable incidence of IV heroin use.
984-24 Temporal Trend of Infective Endocarditis in Chinese: A 
Population Based Study Over 10 Years Period
Kai Hang Yiu, Chung Wah Siu, Kathy Lai Fun Lee, Linda Lam, Raymond Hon Wah 
Chan, Stephen Wai Lun Lee, Chu Pak Lau, Hung Fat Tse, Queen Mary Hospital, Hong 
Kong, Hong Kong
Background Despite recent advances in diagnosis and treatment of infective endocarditis 
(IE), the incidence and mortality of IE remain unchanged. Recent population studies have 
demonstrated a temporal change in epidemiology of IE in Western countries. However, 
there is limited data on temporal change in epidemiology of IE in Chinese.
Method We retrospectively studied the demographic and clinical data of 172 Chinese 
patients (pts)(mean age 52±17yrs, 113 M) diagnosed with IE using Duke’s criteria in 
1995 to 2004. Trends in incidence, underlying heart disease, causative organisms and 
clinical outcome of IE that occurred in a cohort of 0.3 million population spanning 10 
years were evaluated.
Results The incidence of IE ranged from 3.5 to 5.6 cases per 100,000 person-yrs 
and did not change signiﬁcantly over time (P >0.05). There was a signiﬁcant trend for 
increasing age from 46±18 to 56±17 yrs over time (p<0.01). The underlying etiology 
include intravenous drug addict (IVDA, 30%), rheumatic heart diseases (RHD, 17%), 
prosthetic heart valve (9%), congenital heart diseases (9%), mitral valve prolapse (8%), 
degenerative valvular diseases (5%) and others (1%). There were no signiﬁcant trends 
in incidence of underlying etiologies (p>0.05). The majority of IE in IVDA were caused by 
Staphylococcus aureus (79%). For non-IVDA, the common pathogen was Streptococcus 
viridans (1.9-2.6 cases per 100,000 person-yrs), followed by Staphylococcus aureus (0.3 
to 2.0 cases per 100,000 person-yrs). There was an increasing trend for Staphylococcus 
aureus (p<0.05), but not for Streptococcus viridans (p>0.05). Valvular surgery was 
performed in 13% pts and in-hospital mortality and stroke occured in 19% and 12% pts, 
resp. Multivariate analysis showed only age (OR 1.03, p=0.03) and aortic valve IE (OR 
3.36, p<0.01) were independent predictors for major events (mortality + stroke).
Conclusion Our population-based study demonstrated a trend for increasing age and 
incidence of community-acquired Staphyloccocus aureus IE in Chinese pts with IE. In 
contrast to Western population, there were no signiﬁcant changes in the underlying 
etiologies for IE, likely due to a high prevalence of IVDA and RHD related IE in our 
population.
984-25 Infectious Endocaritis Is Independently Associated With 
Type II Diabetes Mellitus
Mohammad-Reza Movahed, Mehrtash Hashemzadeh, M. Mazen Jamal, University of 
California, Irvine Medical Center, Orange, CA
Background: Patients with diabetes mellitus (DM) are at increased risk of infection. 
However, there are no reports about DM association with infectious endocarditis. We 
evaluated the occurrence of endocarditis in patients with DM using a matched control.
Method: Treatment ﬁle (PTF) documents of inpatients’ admission ﬁles that contained 
discharge diagnosis (ICD-9 codes) from all Veterans Health Administration (VHA) 
hospitals were used for this study. The ICD-9 code for DM (293,124) and a control group 
with ICD-code for hypertension (HTN) but no DM (552,623) were used for comparison. 
The occurrence of infectious endocarditis was studied in both cohort using ICD-9 codes 
for endocarditis. Multivariate analysis was performed adjusting for chronic and acute renal 
failure (CRF,ARF) and aortic and mitral valve disease. Continues variables and binary 
variables were analyzed using �2 and Chi square tests.
Results: Endocarditis was present in 1,340 (0.5%) of DM patients vs in 1,412 (0.3%) 
of the control group. Using multivariate analysis adjusting for renal failure and valvular 
abnormalities, DM remained independently associated with endocarditis (OR: 1.9; CI: 
1.8 to 2.1; p<0.0001). Conclusion: Patients with Type II DM have signiﬁcantly higher 
prevalence of endocarditis independent of CRF, ARF or valvular abnormalities. This 
results is consistent with increase vulnerability of DM patients for serious infections.
984-26 Baseline Characteristics Associated With Embolism in 
Infective Endocarditis
Nagesh S. Anavekar, Nandan S. Anavekar, Imad Tleyjeh, Zaur Mirzoyev, Christopher 
Haddad, Masud Kandakher, Jamil Tajik, Walter Wilson, James M. Steckelberg, 
Krishnaswamy Chandrasekaran, Larry M. Baddour, Mayo Clinic, Rochester, MN, 
University of Melbourne, Melbourne, Australia
Background: Risk of embolism in infective endocarditis (IE) is partly related to vegetation 
size and mobility. Other potential explanatory factors for this event are less deﬁned.
Methods: A retrospective study of adult patients with a diagnosis of IE who presented 
to the Mayo Clinic, Rochester, between 1980-1998. The primary endpoint was the initial 
in-hospital embolic event following IE diagnosis. Embolic event was deﬁned as stroke or 
other systemic embolism. Using multivariable logistic regression analysis, 30 baseline 
characteristics determined a priori were analysed for their potential relationship to 
embolism.
Results: One hundred and forty-seven (24.5%) of 600 patients suffered at least one 
embolic event and the most common (48.2%) embolic manifestation was stroke. 
Independent variables that accounted for increased odds of an embolic event 
included: male gender, infection with Staphylococcus aureus, history of prior stroke, 
and polymicrobial infection (Table). Of these, prior stroke [OR 4.24, CI 2.44-7.36; p < 
0.001] and polymicrobial infection [OR 6.40, CI 1.71-23.93; p=0.006] were signiﬁcantly 
associated with embolism. Presence of a prosthetic valve was associated with a reduced 
odds for embolism [OR 0.40, CI 0.22-0.73; p=0.002]. 
Variable Odds ratio 95% Conﬁdence interval P value
Prosthetic valve 0.40 0.22 - 0.73 0.003
Male gender 1.68 1.06 - 2.69 0.029
Polymicrobial infection 6.40 1.71 - 23.93 0.006
S.. aureus 2.08 1.26 - 3.43 0.004
Prior history of stroke 4.24 2.44 - 7.36 <0.0001
Conclusions: Among individuals with IE, history of prior stroke and polymicrobial 
infection are signiﬁcantly associated with risk for embolism.
984-27 Adverse Clinical Outcomes in Left-sided Infective 
Endocarditis Complicated Intravenous Drug Addict
Kai Hang Yiu, Chung Wah Siu, Kathy Lai Fun Lee, Linda Lam, Raymond Hon Wah 
Chan, Stephen Wai Lun Lee, Chu Pak Lau, Hung Fat Tse, University of Hong Kong 
Queen Mary Hospital, Hong Kong, Hong Kong
Background: Right-sided infective endocarditis (IE) is a well known complication of 
intravenous drug addict (IVDA). Previous studied suggested that IVDA can also developed 
left sided IEs, however, limited data on their prevalence and clinical characteristics are 
available.
Method and Results We compared the demographic data, clinical characteristics 
and outcomes between right and left sided IE in IVDA as diagnosed by Duke’s criteria 
presented from 1995 to 2004. Over this 10 yr period, 47 IVDA presented with IE (2.2 per 
100,000 population) in which 35 (74%) and 12 (26%) pts suffered from right and left sided 
IE, respectively. None of them have underlying heart diseases. For right sided IE, tricuspid 
valve was involved in all pts. For left sided IE, mitral and aortic valves were affected in 
equal numbers ( 6 pts each). There were no signiﬁcant differences in age (40±11 vs. 42±11 
yrs, P=0.67), prevalence of male (94 vs. 83%, P=0.24), and Staphylococcus infection (86 
vs. 76%, P=0.39) between pts with right and left sided IE. However, HACEK group and 
fungus infections were more common in pts with left sided IE compared to right sided 
IE (17% vs. 0%, P=0.06). Furthermore, left sided IE was associated with a signiﬁcantly 
higher incidence of major events (stroke + death) as compared to right sided IE (58 vs. 
14%, P=0.003), mainly due to increasing incidence of stroke (27 vs. 3%, P=0.037). In this 
study, no pts underwent surgical treatment for their IE.
Conclusion Left sided valvular involvement occurred in up to 26% of IVDA with IE. 
Although the demographic features and major pathogen were similar between right and 
left sided IE, IVDA with left sided IE had a higher incidence of major adverse events, 
mainly due to increasing incidence of stroke complicated IE. Whether early surgical 
intervention in left sided IE complicated IVDA can prevent adverse outcome requires 
further study.
ORAL CONTRIBUTIONS
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824-4 Valve Type and Long Term Outcomes After Aortic Valve 
Replacement in Older Patients
Erik B. Schelbert, Mary S. Vaughan-Sarrazin, Karl F. Welke, Gary E. Rosenthal, 
University of Iowa, Iowa City, IA, Oregon Health and Science University, Portland, OR
Background: Randomized trials comparing mechanical (M) and bioprosthetic (BP) 
valves for aortic valve replacement (AVR) found better long term outcomes with M valves. 
However, these trials are limited by small sample sizes and study populations that are 
substantially younger than most patients undergoing AVR. Since risks associated with 
each valve type are age-dependent, the generalizability of these trial results to older 
patients is unknown. To address these limitations, we conducted a large long term 
observational study of older patients undergoing AVR.
Methods: Patients 65 years and older undergoing AVR during 1991-2003 (n=319,158) in 
1,216 US hospitals were identiﬁed in Medicare Part A data. Valve type was identiﬁed by 
ICD-9-CM codes for bioprosthetic (35.21) and mechanical (35.22) valves. Cox regression 
models identiﬁed hazards of 1) death (n=135,470; 44%), 2) hospital readmissions for 
either hemorrhage (n=69,134; 22%), stroke (n=19, 417; 6%), embolism (n=9,678; 3%), 
or repeat AVR (n=4,126; 1.3%), 3) hospital readmission for any of these complications 
(n=95,235; 31%) associated with receipt of a BP valve. Models adjusted for demographics, 
socioeconomic status, comorbidity, and the hospital where AVR occurred; patient follow-
up extended to 13 years.
Results: While recipients of BP valves (37%) were older (77 vs. 75 yrs, p<0.001), after 
adjustment, patients receiving BP valves had a 5% lower risk of death [hazard ratio 
(HR)=0.95; 95% CI 0.93-0.97] and an overall 11% lower risk of subsequent readmission 
for any complication [HR 0.89 95% CI 0.88- 0.91] . Patients receiving BP valves had 
lower risks of hemorrhage [HR=0.86; 95% CI 0.84-0.88],], stroke [0.89; 95% CI 0.86-
0.92], and embolism [0.92; 95% CI 0.88-0.97], but higher risk of repeat AVR [1.26; 95% 
CI 1.16-1.37].
Conclusions: In a large observational study of Medicare beneﬁciaries that accounted for 
patient and hospital-level factors with follow-up extending to 13 years, patients receiving 
BP valves had a modestly lower risk of death, lower rates of subsequent stroke, embolism, 
and hemorrhage, but higher risk of repeat AVR. Given the low rate of repeat AVR, these 
data support broader use of bioprosthetic valves in older patients.
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824-5 Prosthesis-Patient Mismatch Affects Long-Term 
Survival After Mechanical Aortic Valve Replacement
Shauline Mohan, Shun Kohsaka, Ariadna Contreras, Vei-Vei Lee, Ross M. Reul, 
George J. Reul, Stephanie A. Coulter, Texas Heart Institute, Baylor College of Medicine, 
Houston, TX, Boston University, Boston, MA
Background: Prosthesis-Patient mismatch (PPM) has been shown to predict short-term 
mortality following aortic valve replacement (AVR) when deﬁned by effective oriﬁce area 
(EOA) / body surface area (BSA). However, mismatch deﬁned by internal geometric area 
/ BSA has not been shown to affect long-term mortality.
Methods: We retrospectively examined long-term survival in 446 patients following 
mechanical AVR at the Texas Heart Institute implanted from 1993 to 1998. We stratiﬁed 
outcome by severity of PPM deﬁned as follows: mild (EOA/BSA >0.85), moderate (0.65-
0.85), and severe (<0.65).
Results: Mean follow up was 6.7 years with mean age of 55.8 y/o, EF of 48.7%, BSA 
of 1.96, and clamp time of 51.5 min. Signiﬁcant PPM (moderate or severe) was found in 
43.5% of this cohort. Patients with mismatch had higher BSAs (1.95 vs. 2.11; p=0.0092), 
and increased incidence of hypertension. There were no differences in incidence of 
COPD, diabetes, prior MI, clamp time, and urgent procedures. Severe mismatch was 
found in 14/19 patients with AVR size =< 21mm. There was no gender difference in this 
high-risk group. Long-term mortality was strongly associated with the presence and 
severity of PPM by Log-Rank test (Table).
Conclusions: PPM is a strong predictor of long-term survival among patients undergoing 
mechanical AVR. PPM is most likely to occur in small valve sizes which can be avoided 
at the time of surgery.
Prosthesis-Patient 
Mismatch
Effective Orﬁce Area / Body 
Surface Area
Long-Term 
Survival
Mild >0.85 76.6% (193/252)
P=0.01Moderate 0.65-0.85 63.4% (111/175)
Severe <0.65 47.4% (10/19)
4:39 p.m.
824-6 Risk Factors Associated With Mortality and Re-
Operation in 252 Patients With AVR for Congenital 
Bicuspid Aortic Valve Disease
Trento Alfredo, Lawrence S.C. Czer, Sorel Goland, Mick De Robertis, James Mirocha, 
Robert M. Kass, Sharo Raissi, Gregory Fontana, Wen Chang, Cedars-Sinai Medical 
Center, Los Angeles, CA
Objective. Limited information is available regarding clinical outcomes and the incidence 
of aortic complications in patients with a dilated ascending aorta (AA) and aortic valve 
replacement (AVR) in patients with bicuspid valve disease (BVD).
Aim. The present clinical study sought to determine the main risk factors associated with 
mortality and incidence of aortic complications in this patient population.
Methods. We reviewed 252 patients with BVD undergoing AVR at our institution from 1971 
through 2000. Patients undergoing concomitant replacement of the AA were excluded.
Results. The average patient age was 60 ± 15 years, 66.3% were male and 40% of 
patients had coronary artery disease (CAD). Aortic stenosis was the predominant lesion 
in 50.4%, aortic regurgitation in 12.4% and mixed in 37.2% patients. Mean follow-up was 
8.9 years. Overall early mortality was 1.5%; 5, 10, 20 year survivals were 83%, 67% 
and 47%, respectively. The normal AA (<4.0 cm) was in 60.3% , mildly dilated (4.0-4.4 
cm) in 24.2% , and moderately dilated (4.5-4.9 cm) in 15.5% of patients. Patients with 
moderate AA dilation had less CAD (p=0.02) and LVEF <40% (p=0.04). Long-term (5, 10 
and 15 year) survival was obtained in the 3 groups; normal aorta (78%, 59%, 37%), mild 
(88%, 77%, 46%) and moderate AA dilation (92%, 83%, 70%), p=0.004. After adjusting 
for CAD and decade of surgery no more differences were seen. The predictors of survival 
using the Cox regression model were CAD (hazard ratio (HR) 2.18, p<0.001),age (HR 
1.05, p<0.001), LVEF <40% (HR 0.98, p=0.019), surgery decade (HR 0.647, p=0.006). 
Aortic dilation entered but was no longer signiﬁcant once the remainder of variables 
were included. At follow-up, 18 patients required reoperation, 16(89%) for aortic valve 
prosthesis failure and 1(5.6%) patient for AA aneurysm.
Conclusions: No difference in survival was found between groups with normal, mildly 
and moderately dilated ascending aorta after adjusting for age, CAD, EF and decade of 
surgery in patients with congenital bicuspid aortic valve. Prospective studies with serial 
ascending aorta evaluation have to be considered to deﬁne the need of concomitant 
replacement of the ascending aorta in this patient population.
4:51 p.m.
824-7 Low Molecular Weight Heparin in Chronically 
Anticoagulated Patients After Mechanical Valve 
Replacement Prior to Interventions With High-Risk of 
Bleeding: Experience in 104 Patients From the BRAVE-
Registry
Christoph Hammerstingl, Gerlinde Schlang, Christina Platen, Angelika Schmitz, Kyung 
Mi Jeong, Heyder Omran, St. Marien Hospital Bonn, Bonn, Germany
Background: It is recommended to discontinue oral anticoagulation (OAC) in chronically 
anticoagulated patients (pts) after mechanical valve replacement prior to interventions 
with high risk of bleeding. To prevent thromboembolic (TE) complications pts should 
receive weight adapted bridging therapy with unfractioned heparin i.v.. Low molecular 
weight heparin (LMWH) have a higher bioavailability and more predictive anticoagulatory 
effect, therefore, effective anticoagulant therapy can be achieved by subcutaneous 
application of LMWH. Bridging therapy with weight adapted LMWH s.c. in pts after valve 
replacement is increasing, although these pts are at substantially high TE-risk. The aim 
of this registry was to assess the safety and feasibility of bridging therapy with LMWH in 
those pts.
Methods: Chronically anticoagulated received weight adapted enoxaparin s.c. twice a 
day (0,1mg/kgBW/12h). Procedures were performed at INR<1.5. After the procedure OAC 
was reintroduced under continued LMWH therapy until effective INR was reachieved. 
Bleeding complications, occurence of thromboembolism and other adverse events under 
therapy were assessed.
Results: 104 pts were treated with enoxaparin, n= 66 mechanical aortic valve 
replavement, n = 28 mitral valve replacement, and n = 8 double valve replacement. Age 
77.2 ±11.1 y; male n= 60, mean treatment time 7.3±4.8 d, creatinine clearance 98.5±39.7. 
23 pts underwent major surgery, 81 minor surgery or other interventions with elevated 
bleeding risk. In 9 pts occured minor bleeding, 0 major bleeding. No thromboembolic 
complication evolved due to briding therapy.
Conclusions: Bridging therapy of low molecular weight heparin (enoxaparin) after 
mechanical valve replacement is safe and feasible in a large cohort of patients. Therapeutic 
low molecular weigh heparin treatment seems to be an alternative to standard therapy 
with unfractioned heparin.
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Percutaneous Procedures
Tuesday, March 14, 2006, 8:30 a.m.-Noon
Georgia World Congress Center, Hall B1
Presentation Hour: 11:00 a.m.-Noon
1006-19 Percutaneous Septal Sinus Shortening (The PS3 
SystemTM) Ameliorates Functional Mitral Regurgitation
Jason H. Rogers, John Macoviak, Patricia Takeda, David Rahdert, Reginald Low, UC 
Davis Medical Center, Sacramento, CA, Ample Medical, Inc., Foster City, CA
Background Prior research has demonstrated that the septal-lateral (S-L) mitral annular 
diameter is increased in functional mitral regurgitation (FMR). We have developed a novel 
peructaneous technique (percutaneous septal sinus shortening or PS3 System) which 
ameliorates FMR in an ovine model.
Methods Sheep underwent rapid RV pacing to obtain moderate-severe FMR with S-
L enlargement. The procedure was performed under ﬂuoroscopic and intracardiac 
echocardiographic guidance. Placing the PS3 SystemTM using magnetic catheters, a 
bridge (suture) element is positioned between interatrial septal wall and great cardiac 
vein anchors. By progressively tensioning this bridge element, direct S-L shortening may 
be achieved.
Results Sheep underwent acute (n=19) and chronic (n=4) evaluation after device 
implantation. In acute studies, there was an average 24% reduction in the S-L diameter 
with reduction of MR from 2.1+ to 0.4+. Chronic (30 day) device implantation demonstrated 
durable S-L shortening and reduction in MR despite continued rapid pacing (Figure 
1). There was increased cardiac output and decreased wedge pressure in animals 
undergoing chronic device implantation.
Conclusions The PS3 System is effective in the amelioration of FMR in an ovine model. 
The procedure utilizes standard catheter techniques and can be deployed largely under 
ﬂuoroscopic guidance. In addition, the bridge element allows direct and precise S-L 
shortening to a diameter optimal for MR reduction.
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1006-20 Percutaneous Edge-to-Edge Mitral Valve Repair 
Using the Evalve® MitraClip™: Initial Experience With 
Functional Mitral Regurgitation in the EVEREST I Trial
Peter C. Block, Howard C. Herrmann, Patrick L. Whitlow, Paul Kramer, Hal S. 
Wasserman, William A. Gray, Elyse Foster, Ted Feldman, Emory University Hospital, 
Atlanta, GA
Background: Edge to edge repair without annuloplasty in patients with functional mitral 
regurgitation (FMR) has been controversial. The Evalve Endovascular Valve Edge-to-Edge 
REpair Study (EVEREST I) was a Phase I study for repair of MR using a percutaneous 
transseptal approach. Methods: Surgical candidates with moderate-severe (3+) or severe 
MR (4+) with symptoms, or asymptomatic with EF 45 mm, were included. Exclusions 
included EF 55 mm, endocarditis, and rheumatic heart disease. The efﬁcacy endpoint 
was core lab MR severity <2+. In the Phase I study cohort were 6 patients (pts) with 
FMR deﬁned as absence of structural valve disease as cause of MR who form the basis 
of this report. Results: All 6 pts were NYHA class III, 3 had one or more prior median 
sternotomy. Mean EF was 52±10% (range 40-64); mean LVIDs was 46±6mm (range 36-
51). All (100%) had clips implanted; one received 2 clips. No 30-day major adverse events 
occurred. By 30 days, NYHA class was reduced in 5 and unchanged in 1. MR data are 
reported in the table. After 1 month, all were improved: 4 with 1+, 1 with 2+ and 1 with 3+ 
MR. Two pts have reached 12 months follow-up; both have core-lab MR <2+.
Conclusion: Percutaneous edge-to-edge mitral valve repair with the MitraClip can 
be accomplished successfully in pts with FMR. In this population, MR can be reduced 
without major adverse events.
Table 
MR grade Pre-MitraClip# patients
30 day post
# patients
MR = 4+ 2 0
MR = 3+ 4 1
MR = 2+ 0 1
MR = 1+ 0 4
 
1006-21 Pulmonary Hypertension With Excessive 
Transpulmonary Gradients Among Mitral Stenotics: 
Prevalence and Clinical Outcome Following 
Percutaneous Balloon Mitral Commissurotomy
Richard A. Krasuski, Andrew Wang, Katherine Kisslo, J. Kevin Harrison, Thomas M. 
Bashore, Cleveland Clinic Foundation, Cleveland, OH, Duke University, Durham, NC
Background: Pulmonary hypertension (PH) in a wide variety of disease processes may 
be based on a similar genetic substrate. It is well known that a subset of mitral stenotics 
have PH in excess to their mitral valve hemodynamics. The prevalence of this condition 
and clinical outcome of these patients after valvuloplasty is unknown.
Methods: In 317 patients undergoing Inoue PBMC, transpulmonary gradient (TPG) 
was measured and patients deﬁned as having appropriate (≤ 15 mm Hg) or excessive 
(>15 mm Hg) TPG. Twenty-two patients were excluded because of hemodynamically 
signiﬁcant, valvuloplasty-related mitral regurgitation. Patients were prospectively followed, 
with 6-month and subsequently yearly visits and echocardiography.
Results: Among the 295 patients, 80% had PH (mean pulmonary artery pressure >25 
mm Hg) prior to valvuloplasty and 18.6% (55 patients) had excessive TPG. Compared 
with patients having appropriate TPG, patients with excessive TPG were similar in age 
(~52 years), signiﬁcant co-morbidities, systemic blood pressure, cardiac index and mitral 
valve echo score. Excessive TPG was nearly 4 times more common in women than men 
(p=0.025). Patients with excessive TPG had slightly smaller mitral valve oriﬁces (1.0±0.2 
vs. 1.1±0.2 cm., p=0.003), more symptoms (NYHA class 3.0±0.5 vs. 2.7±0.6, p=0.010), 
higher mean right atrial (9.4±4.6 vs. 7.6±3.4, p=0.005) and mean pulmonary artery 
pressures (48.4±12.0 vs. 29.1±7.0 mm Hg, p<0.0001) and higher pulmonary vascular 
resistance (5.0±2.4 vs. 1.4±1.3 Wood units, p<0.0001). Valvuloplasty success was similar 
in both groups (ﬁnal mitral valve area 1.7±0.6 vs. 1.8±0.4 cm., p=0.103) but resulted in 
a greater drop in pulmonary pressure at the time of valvuloplasty in the excessive TPG 
group (14% vs. 7%, p=0.005). At 6 months follow-up NYHA class no longer differed and 
remained similar at 3 years.
Conclusions: Pulmonary hypertension with excessive transpulmonary gradient is 
common in patients with mitral stenosis, and women appear to have a much greater risk 
of developing this problem. Despite higher right-sided pressures and worse symptoms, 
mitral valvuloplasty is equally successful and provides sustained beneﬁt in this population 
of patients.
1006-22 The Incidence of Aortic Regurgitation After 
Percutaneous Aortic Valve Implantation
George S. Hanzel, Amr Abbas, Simon R. Dixon, Jeffrey W. Moses, Martin B. Leon, John 
G. Webb, Alain Cribier, William W. O’Neill, William Beaumont Hospital, Royal Oak, MI
Background: Precutaneous aortic valve replacement is an exciting and promising new 
technology for the treatment of critical aortic stenosis in high-risk surgical candidates. It 
has been suggested that paravalvular aortic regurgitation (AR) may limit the success of 
the procedure.
Methods: Between April 2002 and April 2005 51 Cribier-EdwardsTM Percutaneous 
Heart Valves (PHV) were implanted worldwide. We retrospectively analyzed all 51 
cineangiograms. The degree of AR after PHV implant was independently assessed by two 
investigators (GSH and AA). Differences were adjudicated by a third investigator (SRD).
Results: Nine of the 51 angiograms were uninterpretable. Of the 45 cases analyzed a 23 
mm diameter PHV was implanted in 41 patients and a 26 mm diameter PHV was used in 
4 patients. The incidence and degree of aortic regurgitation are shown in Table 1. Overall, 
46% of patients had 3+ or 4+ AR.
Conclusions: Signiﬁcant (3+ or 4+) AR is common after Cribier-EdwardsTM PHV 
implantation. It is noteworthy that AR > 1+ was seen with a larger diameter PHV. 
Appropriate device sizing and advanced device designs may reduce the incidence and 
degree of AR after PHV implantation.
Aortic Regurgitation After PHV Implantation
AR Grade 23 mm PHV (n=41) 26 mm PHV (n=4)
0 3 (7.3%) 2 (50.0%)
1+ 3 (7.3%) 2 (50.0%)
2+ 14 (34.1%) 0 (0%)
3+ 16 (39.1%) 0 (0%)
4+ 5 (12.2%) 0 (0%)
1006-23 Coronary Sinus Stent Implantation Improves Ischemic 
Mitral Valve Regurgitation: An Experimental Study
Athanasios Magginas, Stefanos Karagiannis, George Karatasakis, Apostolos Papalois, 
Anastasios Papalamdrou, Paraskevi Daphnomili, Loukas Kaklamanis, Lubna Chaldi, 
Dennis V. Cokkinos, Onassis Cardiac Surgery Center, Athens, Greece
Intoduction: Mitral valve regurgitation causes volume overload and leads to further 
deterioration in symptomatic heart failure. We sought to determine the effect of 
a percutaneous mitral anulloplasty device (stent) in the coronary sinus of pigs in 
experimental ischemic mitral regurgitation (IMR). 
Methods: We studied 5 consecutive male pigs (weight 20±5kg). All were anesthetized, 
intubated and were catheterized through the right femoral artery. An angioplasty balloon 
was repeatedly inﬂated in the proximal left circumﬂex artery for ﬁve minutes, and mitral 
regurgitation was estimated by transthoracic echo measuring color jet area, regurgitant 
ﬂow and proximal isovelocity surface area (PISA) radius. The balloon inﬂation and the 
MR assessment were repeated 3 times at baseline. Consequently a large (8,9-9,0 mm) 
diameter stent was implanted in the coronary sinus through the right femoral vein and 
the degree of IMR was again evaluated. The measurements after stent placement were 
repeated 3 times, and the values were averaged.
Results: Following stent implantation there was IMR improvement in all pigs (table).
Table
MR area cm2 PISA MRﬂow ml/sec PISA radius cm
Pre-stent
(mean values ± SD) 2.36±0.37 63.9±37.27 0.46±0.079
Stent
(mean values ± SD) 1.12±0.60 44±35.00 0.30±0.053
p value 0.016 0.029 0.09
Three animals were allowed to recover and histology was performed at 30 days, 
documenting endotheliolization of the coronary sinus stent without thrombosis.
Conclusion: Percutaneous mitral annuloplasty by coronary sinus stent implantation is 
feasible and improves experimental acute IMR.
1006-24 Favourable Effect of Mitral Balloon Valvuloplasty on the 
Incidence of Atrial Fibrillation in Patients With Severe 
Mitral Stenosis
Mohamed Eid Fawzy, Hani Al Sergani, Adil Osman, Abdulmoniem ElDali, Bahaa Fadel, 
Mohammad Kandeel, Charles C. Canver, King Faisal Heart Institute, Riyadh, Saudi 
Arabia, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia
Background and Aims: Atrial ﬁbrillation (AF) is a frequent complication of mitral stenosis 
(MS) with variable prevalence rate (29% to 75%). There is paucity of data of the effect of 
mitral balloon valvuloplasty (MBV) on the incidence of AF. The aims of this study were to 
evaluate the effect of successful MBV on the incidence of AF in patients with severe MS 
in comparison with the historical control and assess its predictors.
Methods: Between December 1989 to 2003, 385 consecutive patients with severe MS 
and in sinus rhythm (SR) underwent successful MBV at KFSH and were followed up for 
1.0 to 15.6 (mean 5.6 ± 3.9) years with clinical and echocardiographic examination.
Results: The baseline data and immediate and long-term follow-up results are shown in 
Table 1. 34 patients (8.8%) (group A) went into AF at follow-up and 351 remained in SR. 
Stepwise Cox multivariable analysis identiﬁed age at follow-up (P = 0.002) pulmonary 
artery pressure (P = 0.002) echo score (P = 0.001) MVA at follow-up (P = 0.02), left atrial 
(LA) size at follow-up (P = 0.0004) as predictors of occurrence of AF.
Conclusions: (1) MBV has favourable effect on the incidence of AF in patients with severe 
MS (8.8% in comparison to historical control (29%) in severe MS without intervention and 
similar age; (2) patients who went into AF had higher echo score and inferior immediate 
and long-term results, larger LA and higher restenosis rate.
Table Legends: B=baseline; I=immediately after MBV; F=follow-up; *P=<0.0001; +P=not 
signiﬁcant
Table 1
Parameter Total Group (n=385)
Group A 
(n=34)
Group B 
(n=351) P Value
Age (year) Β 29.5± 9.8 36.5 ± 10.6 28.8 ± 9.5 <0.0001
F 35.1 ± 10.5 43.5 ± 11.6 34.3 ± 10 <0.0001
Mitral valve area cm2 
(MVA) B 0.9 ± 0.2 0.9 ± 0.1 0.9 ± 0.2 0.48
I 2.0 ± 0.3* 1.7 ± 0.3* 2.0 ± 0.3* 0.001
F 1.7 ± 0.4* 1.5 ± 0.4+ 1.8 ± 0.3* <0.0001
Left atrial size mm B 47.4 ± 7.1 49.1 ± 6.0 47.2 ± 7.1 0.15
F 42.8 ± 6.8* 49.4 ± 6.5+ 42.2 ± 6.5* <0.0001
Echo score 7.9 ± 1.1 8.4 ± 0.9 7.8 ± 1.1 0.002
Restenosis rate 60 (15.7%) 12 (35%) 48 (13.8%) 0.001
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1006-25 Concurrent Percutaneous Balloon Valvuloplasties in 
Combined Rheumatic Mitral and Tricuspid Stenosis: 
Our Experience of Different Techniques
Sunil V. Sathe, Manuvel Durairaj, Chandrashekhar N. Makhle, Archana S. Sathe, 
Rituparna S. Shinde, Ajit C. Mehta, Purvez K. Grant, Murugesh S. Hiremath, Ruby Hall 
Clinic, Grant Medical Foundation, Pune, India, Marian Cardiac Centre & Research 
Foundation, Pune, India
Background: Percutaneous balloon Mitral Valvuloplasty (BMV) is the treatment of choice 
in rheumatic Mitral Stenosis in India irrespective of the age. Co-existing Tricuspid stenosis 
(TS) in patients with mitral stenosis is often found on echocardiographic evaluation.TS 
may preclude clinical improvement despite a successful BMV, if uncorrected. We report 
our experience of concurrent balloon tricuspid Valvuloplasty (BTV).
Methods: A total of 1551 patients underwent BMV at our Centre over the past ﬁve 
years, using Inoue balloon technique. Out of these, 58 cases (3.7%) required tricuspid 
Valve dilatation. There were 36 females and 22males (age 14 - 48 yrs) Three different 
techniques were used:- Group I Inoue balloon size 28 - 30 mm used to dilate the tricuspid 
valve in 20 cases. Group II Mansﬁeld double balloon - placing double length wires in Right 
Pulmonary artery in 26 patients. Group III Mansﬁeld double balloon with guide wires in 
RV in 12 cases.
Results: Good immediate results were obtained in all cases. The mean gradient across 
the Tricuspid Valve decreased from 11 mmHg (range 6 - 18) to 4 mmHg (range 2 - 8 mm) 
after balloon dilatation, 8 patients in group I were converted to Group II after inadequate 
opening by Inoue balloon.
Conclusions: Concurrent balloon dilatation for tricuspid stenosis in combined rheumatic 
Mitral stenosis while performing BMV is essential. Satisfactory & better results obtained by 
utilizing 2 Mansﬁeld balloons with guide in right pulmonary artery which gives maximum 
stability and perhaps superior to other techniques.
1006-26 Long-Term Outcome in Patients With Ischemic Mitral 
Regurgitation Undergoing Percutaneous Coronary 
Intervention
Catherine A. Pastorius, Paul Sander, Timothy D. Henry, Jessica A. Wilson, Denise 
Windenberg, Howard Liang, Thomas Knickelbine, Kevin M. Harris, Minneapolis Heart 
Institute Foundation, Minneapolis, MN
Background: Appropriate treatment for patients with ischemic mitral regurgitation (MR) 
is often debated. Evidence suggests that MR has prognostic importance in patients 
undergoing coronary artery bypass surgery. Long term outcome of those undergoing 
percutaneous coronary intervention (PCI) is less well deﬁned.
Methods: We evaluated patients who underwent PCI at our institution in the year 2000 
and had qualitative assessment of MR by left ventriculography and/or echocardiography. 
Perioperative death was recorded and 1 and 5 yr mortality was determined by social 
security death index. MR severity was divided into three strata: none (n=435, 58%), mild 
(n=228, 30.4%), and moderate to severe (n=87, 11.6%).
Results: The cohort included 750 patients with an average age of 64.5±12.4 years 
and 478 (63%) were males. Patients with progressively more severe MR were older 
(p<0.0001), more frequently female (p<0.0001),with lower left ventricular ejection 
fraction (EF) of 45±14.2 (p<0.0001), higher incidence of previous myocardial infarctions 
(p<0.002), and higher creatinine (p<0.02). Decreased survival rates were associated with 
increasing MR severity (none versus mild versus moderate-severe) at 30 days (100% vs. 
98.7% vs. 96.6% respectively; p<0.0025), one year (99.5%, 92.5%, 86.2%; p<0.0001), 
and ﬁve years (97%, 83.3%, 57.5%; p<0.0001). A Cox regression model was used to 
evaluate survival time and prognostic factors and found that the presence of MR was 
the most important predictor of survival,(regression coefﬁcient 1.78, p<0.0001); more 
important than EF (-0.03, p<0.0001), age (0.05 p<0.0001) and gender.
Conclusions: Patients with ischemic MR undergoing PCI have signiﬁcantly decreased 
survival rates over ﬁve years and MR is an important predictor of survival. Given a 5 year 
survival of only 58% for patients with moderate to severe MR, further study will need to 
evaluate whether concomitant percutaneous valve repair or coronary artery bypass with 
repair would improve outcome in patients requiring revascularization.
1006-27 First Experience With a New Self Expanding Aortic 
Valve Prosthesis for Percutaneous Treatment of Aortic 
Valve Disease in High Risk Patients
Eberhard Grube, Jean Laborde, Ulrich Gerckens, Lutz Buellesfeld, Stein Iversen, Heart 
Center Siegburg, Siegburg, Germany
Background: Percutaneous aortic valve replacement is a new promising technology for 
patients with signiﬁcant aortic valve stenosis and high risk for surgery. We report the results 
of the ﬁrst 18 patients (pts) treated with the new CoreValve prosthesis, which is composed 
of three bovine pericardial leaﬂets inserted within a self-expanding nitinol stent.
Methods and Results: A retrograde approach via the common iliac artery was used 
for the valve deployment. Clinical, hemodynamic, and echocardiographic outcomes 
were assessed serially during the procedure. Echocardiographic follow-up to 180 days 
after prosthesis implantation were performed to evaluate the short-term outcome. The 
prosthesis was successfully deployed within the diseased native aortic valve in 14 of 18 
pts, two patients died peri-interventionally (one pt prior to device implantation, one pt at 
day two post implantation with delayed pericardial hemorrhage). Two pts were converted 
to surgery due to unsuccessful device placement. 2D and doppler echo immediately after 
device deployment showed a signiﬁcant reduction in transaortic peak pressure gradient 
from 73.9 +/- 24.6mmHg to 14.3+/-11.2mmHg in the patient population with initial 
technical success (14 pts). In the in-hospital follow-up, 5 pts died (crush-syndrome (1), 
multi-organe failure (2), pulmonary insufﬁciency due to lung cancer (1), cerebrovascular 
insufﬁciency (1)). The in-hospital mortality ranged from 6/11 in the early phase I (multi-
center, very high risk patients) to 1/7 in the ongoing study phase II (single-center). All pts 
developed temporary thrombocytopenia, that was persistent if antiplatelet medication was 
not given. Pts with clopidogrel and ASS showed restoration of normal platelet counts after 
4-8 days. The 9 pts with uneventful in-hospital follow-up were discharged with signiﬁcant 
improvement of the clinical status. The 14 day follow-up was uneventful in all 9 pts. The 
completed results will be presented.
Conclusion: This ﬁrst experience with a self-expanding aortic valve prosthesis using the 
retrograde approach conﬁrms the concept with a promising acute device success rate 
and immediate improvements of the hemodynamic status.
ORAL CONTRIBUTIONS
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11:00 a.m.
844-3 Human Degenerative Valve Disease is Associated 
with Upreguation of Lrp5 Receptor Mediated Bone 
Formation
Nalini M. Rajamannan, Frank C. Caira, Stuart R. Stock, Malayannan Subramaniam, 
Thomas Gleason, Edward McGee, Brett Sheridan, Craig Selzman, Robert O. Bonow, 
Shahbudin H. Rahimtoola, Patrick M. McCarthy, Thomas C. Spelsberg, Northwestern 
University, Chicago, IL, Mayo Clinic, Rochester, MN
Background: “Degenerative” valvular heart disease is the primary cause of regurgitant 
and stenotic valvular lesions in the World. However, the cellular mechanisms are unknown. 
We hypothesize that valve degeneration occurs due to a chrondrocytic differentiation 
process mediated by the Lrp5 receptor to cause valve thickening via Wnt Signaling. 
Methods: We examined human diseased valves: myxomatous mitral valves (MV) (N=23), 
calciﬁed aortic valves (AV) (N=27), and control tissue AV and MV (N=40). The valves 
were examined by RTPCR,Western blot and immunohistochemistry for signaling markers 
important in chondrocyte differentiation: Sox9 (transcription factors for chondrocyte 
differentiation); Lrp5 (chondrocytic differentiation pathway); osteopontin and osteocalcin 
(chrondrocytic endochondral bone matrix protein). Cartilage development and bone 
calciﬁcation was assessed by Alacian blue stain and Alizarin red stain. Computed 
MicroCT analysis quantiﬁed calcium burden (0 None-4 Severe). (Results expressed as 
percent of control ( *p<0.05) 
Results: ( See Table) Lrp5 receptor,OCN and calciﬁcation were increased in the 
calciﬁed AV, and Sox 9, Lrp5 recptor and Alacian Blue Cartilage cells were increased 
in myxomatous MV. 
Conclusion: Degenerative valvular heart disease involves an endochondral bone 
process which is expressed as cartilage in the MV and bone in the AV. This process may 
be regulated by the Lrp5 pathway which may contribute to the pathophysiology of valve 
degeneration.
Chondrocytic Markers
p<0.05* Control MV Control AV Myxomatous Mitral Valve Calciﬁed Aortic Valve
Lrp5 64.2% 0 221.3%* 255.3%*
Sox9 59% 118% 117%* 81%
OPN 47% 55% 97%* 88%*
OCN 42% 47% 114%* 129%*
MicroCT 0 0 0 +4
11:15 a.m.
844-4 Angiotensin Receptor 1 Blocker Reduces 
Atherosclerotic Changes of Aortic Valve in 
Hypercholesterolemic Rabbit Model
Kumiko Arishiro, Masaaki Hoshiga, Nobuyuki Negoro, Taichi Okabe, Tadashi Ishihara, 
Toshiaki Hanafusa, Osaka Medical College, Osaka, Japan
Background: Recently calciﬁed aortic stenosis has become more common and 
atherosclerosis is now recognized as a mechanism responsible for this situation. 
Angiotensin receptor blocker (ARB) may be a candidate for prevention of aortic stenosis 
because of its multiple anti-atherosclerotic effects. Little is known about efﬁcacy of ARB 
for this valve disorder. We examined the effect of ARB on atherosclerotic changes of 
aortic valve in hypercholesterolemic rabbit model.
Methods: Male rabbits (n=30) were divided into 3 groups: control (C) with chow diet; 
vehicle (V), 1% cholesterol diet for 8 weeks with CM-cellulose in the last 4 weeks; 
ARB, 1% cholesterol diet for 8 weeks with ARB (olmesartan, 1mg/kg/day, orally) in 
the last 4 weeks. At sacriﬁce, the aortic valve leaﬂets were dissected and examined by 
immunohistochemistry or real-time PCR.
Results: This dose of olmesartan did not change blood pressure nor cholesterol level. In V 
group, aortic valve leaﬂet had fatty deposition with macrophage accumulation. In addition, 
osteopontin, one of osteoblast marker, was highly expressed in valve leaﬂet. These 
ﬁndings were not found in C group. ARB decreased macrophage accumulation (%RAM 
11 positive area; V group: 18±1.2; ARB: 2.6±1.5; p<0.01) and osteopontin expression (% 
area; V group: 17±2.2; ARB: 7.9±1.3; p<0.05) in valve leaﬂet. Real-time PCR revealed that 
osteoblast lineage-speciﬁc marker Cbfa-1 was upregulated by cholesterol feeding and 
ARB reversed its upregulation. Moreover, immunohistochemistry with anti-CD31 antibody 
revealed that cholesterol feeding disrupted the endothelial integrity on the aortic side 
of valve leaﬂet, a lesion-prone side, and ARB preserved its integrity (% CD31-positive 
circumference of valve surface; C group: 66±6.2; V group: 30±3.7; ARB: 62±4.8; p<0.01).
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Conclusions: ARB inhibits atherosclerotic changes of aortic valve in cholesterol-fed 
rabbit with preserving the endothelial integrity of valve leaﬂet. These ﬁndings may have 
important prognostic implications for clinical use of ARB in patients with aortic valve 
stenosis.
11:30 a.m.
844-5 Biochemical Markers of Collagen Turnover in 
Asymptomatic Aortic Regurgitation With Normal EF 
and LV Dimension
Masaru Ichida, Keiji Yamamoto, Yoshioki Nishimura, Kazuyuki Shimada, Jichi Medical 
School, Tochigi, Japan
Background: Observational studies with biopsy material from cardiac catheterization 
and surgery suggest that ﬁbrosis precedes and may be related to the development of 
congestive heart failure in severe aortic regurgitation (AR). Serum concentration of 
biochemical marker of collagen turnover is related to myocardial ﬁbrosis in hypertensive 
patients. Recently, it has been reported that a serological marker of collagen turnover is 
a prognostic factor in congestive heart failure. In this study, we investigated the collagen 
turnover in patients with asymptomatic AR, normal ejection fraction (EF) (>60%) and 
normal left ventricular dimension (LVd) (< 55mm). 
Methods: We determined levels of pyridinoline cross-linked carboxyterminal telopeptide 
of type I collagen (ICTP), a marker of collagen type I degradation, and procollagen 
type III aminoterminal peptide (PIIINP), a marker of collagen type III synthesis, in 10 
control subjects and 22 asymptomatic AR patients, and we also measured BNP and 
IL-6 levels. We determined conventional parameters by transthoracic echocardiography 
and performed tissue Doppler imaging to determine myocardial early diastolic wave (Ea) 
peak velocity at the level of mitral annuls in the apical four chamber view. The relationship 
between serological markers and these echocardiographic parameters was investigated.
Results: BNP level and ICTP level in AR patients were signiﬁcantly higher than those 
in control (BNP, 48.3±12.6 pg/ml vs. 19.7±4.8 pg/ml, p<0.05; ICTP, 3.59±0.26 ng/ml vs. 
2.75±0.19ng/ml, p<0.05). AR patients showed a tendency to increase the PIIINP level 
compare to that of control (0.53±0.02 U/ml vs. 0.47±0.03 U/ml, p=0.21). IL-6 level was 
not different between AR patients and control. In AR patients, Ea velocity was negatively 
correlated with ICTP level (r=-0.513, p<0.05) and had a tendency to be negatively 
correlated with PIIINP level (r=-0.35, p=0.14). 
Conclusions: These results suggest that cardiac ﬁbrosis is proceeding in asymptomatic AR 
patients with normal EF and LV dimension. In addition, the increase in biochemical markers of 
collagen indicates LV diastolic dysfunction, which is shown by decline of Ea velocity.
11:45 a.m.
844-6 Thrombolytic Therapy for Left-Sided Prosthetic Valve 
Theombosis
Ashok K. Omar, Sr., Escorts Heart Institute and Research Centre, New Delhi, India
Background: Thrombosis of left sided prosthetic heart valves is a potentially serious 
complication. Thrombolytic therapy has been proposed as an alternative to surgical 
methods in treating this condition.
Methods: Since January 2000 to March 2005, a study done on 53 patients presented to 
EHIRC with prosthetic valve thrombosis. Under serial 2D-Echocardiographic study a total 
number of 50 patients (57% males, mean age 48-27 years) were treated with intravenous 
thrombolytic therapy. Of which 20 patients had mitral and 30 patients had aortic valve 
thrombosis. 56% patients were in NYHA functional class II and 40% patients were in 
class III. Inadequate anticoagulation was recognized in 96% of patients .The time period 
between valve replacement and thrombosis ranged from 2 months-16 years (mean 30.1-
28 months). Streptokinase was used in 45 patients and Urokinase in 5 patients. The mean 
duration of thrombolytic therapy was 8-9.8 hours.
Results: Success was achieved in 90 % of patients with normalization of valve gradient 
and valve movement. Only one patient died due to persistent heart failure. 3 patients 
underwent Redo-Valve replacement as they did not improve with thrombolytic therapy.
Conclusions:Inadequate anticoagulation is predominant cause of prosthetic valve 
thrombosis in our study. Successful thrombolysis was achieved at low risk of complications 
with IV thrombolytic therapy for both mitral and aortic valve thrombosis and in all types 
of prosthesis. Hence we recommend thrombolytic therapy as a safe and effective non-
surgical method of treatment for prosthetic valve thrombosis.
Noon
844-7 Determinants of the Severity of Functional Tricuspid 
Regurgitation: The Emerging Role of the Right 
Ventricular Geometry
Hyung-Kwan Kim, Yong-Jin Kim, Eue-Keun Choi, Jin-Shik Park, Kyung Hwan Kim, Ki-
Bong Kim, Hyuk Ahn, Dae-Won Sohn, Byung-Hee Oh, Young-Bae Park, Yun-Shik Choi, 
Seoul National University Hospital, Seoul, South Korea
Background: Despite its importance as a prognosticator of cardiac morbidity and 
mortality, the determinants of functional tricuspid regurgitation(FTR) severity have not 
been revealed. We performed a prospective study to determine the factors related to 
FTR severity. 
Methods: We enrolled 64 patients with chronic RV dilation and measured right atrial(RA) 
area, RV area and RV fractional area change(RVFAC), tricuspid valve(TV) annular 
diameter, and RV systolic pressure with echocardiography. We also measured RV 
eccentricity index (RVEI) and sphericity index for simple presentation of RV geometry. 
Regurgitant oriﬁce area of FTR(FTR-ROA) was obtained. 
Results: Univariate analysis showed that end-systole RVEI, end-diastole RVEI, RA area, 
TV tethering area, age, end-systole & end-diastole TV annular diameter, and LV ejection 
fraction were signiﬁcantly related to FTR-ROA. However, RV area, RVFAC, and RV systolic 
pressure were not. In multivariate analysis, end-systole RVEI, TV tethering area, and 
end-diastole TV annulus diameter showed the independent associations with FTR-ROA. 
With ROC curves, the sensitivities and speciﬁcities for predicting >mild FTR were found 
to be 79% and 82% with end-systole RVEI>2, 69% and 73% with end-systole tethering 
area>1cm2, and 64% and 59% for end-systole TV annulus diameter>3.9cm, respectively. 
Conclusions: Degree of FTR showed the best relation to end-systole RVEI. This ﬁnding 
underscores the importance of eccentric RV dilation for determining FTR severity. 
12:15 p.m.
844-8 Assessment of Mitral Regurgitation by CMR Derived 
Regurgitant Volume and Fraction: Is It Superior to 
Echocardiographic ERO?
Ketheswaram Caruppannan, Mark Doyle, June Yamrozik, Ronald Williams, Vikas 
K. Rathi, Diane A. Vido, Geetha Rayarao, Robert W. Biederman, Allegheny General 
Hospital, Pittsburgh, PA
Introduction Recently, the contribution that mitral regurgitation (MR) adds to human 
morbidity and mortality has been the focus of considerable attention by echocardiography 
(Echo). Yet, estimation of MR by Echo has been primarily limited to quantiﬁcation of 
effective regurgitant oriﬁce area (ERO) derived via geometric assumptions from proximal 
isovelocity surface area (PISA).
Hypothesis We hypothesize that the incorporation of one additional PVM plane at the 
level of the aortic valve when combined with standard 3D LV volumetrics will accurately, 
rapidly and easily quantitate MR without reliance on the geometric assumptions of echo, 
and are veriﬁable in a phantom model.
Method 1) A phantom ﬂow pump was used with PVM to correlate quantitated ﬂow (ml/s) 
against calibrated ﬂow. 2) Subjects (35) incorporating 14 normals (average age 43±20), 
and 21 patients with varying degrees of MR (trace - 4+), average age 60±23) underwent 
a 3D LV volumetric CMR (GE CV/i 1.5T) study with an additional trans-aortic thru-plane 
PVM acquisition to quantitate LV stroke volume (SV). Exclusion criteria include aortic 
regurgitation (AR) and any intracardiac shunt lesion. Subtraction of the volumetic derived 
SV (SV3D) from the PVM derived SV (SVPVM) yields, in the absence of AR or shunt, mitral 
regurgitant volume. Regurgitant fraction was deﬁned as (SV3D- SVPVM/ SV3D).
Results The correlation of ﬂow between the phantom model and PVM was 0.98 
(p=<0.001). The correlation in the controls between SV3D and SVPVM was 75±9 vs 
70±10ml, respectively, (r=0.88, p=<0.001). The resultant 3D EF ranged from 13 to 76%. 
The range of Regvol and Regfract was 15ml to 56ml and 15 to 47%, respectively. Quantitative 
MR was highly correlated with clinical qualitative ﬁndings from FIESTA imaging (r=0.9). 
No geometric assumptions were required to derive either Regvol or Regfract.
Conclusion CMR derived quantitation of mitral regurgitant volume and regurgitant 
fraction using aortic PVM in conjunction with 3D quantiﬁed LV stroke volume permit 
accurate, rapid and easily obtained, non-assumption based clinical metrics without 
requirements for assessing the mitral oriﬁce, often subject to errors and erroneous in 
eccentric jets by echo.
POSTER SESSION
1030 
Aortic Stenosis
Tuesday, March 14, 2006, 12:30 p.m.-4:00 p.m.
Georgia World Congress Center, Hall B1
Presentation Hour: 2:30 p.m.-3:30 p.m.
1030-19 Impact of Gender on Left Atrial and Ventricular 
Response to Asymptomatic Aortic Valve Stenosis. The 
SEAS Study
D. Cramariuc, A. E. Rieck, E. M. Staal, E. Eriksen, A. Rossebo, E. Gerdts, Institute of 
Medicine, University of Bergen, Bergen, Norway, Division of Cardiology, Aker University 
Hospital, Oslo, Norway
Background: Women with severe symptomatic aortic valve stenosis (AS) have more 
concentric left ventricular (LV) geometry than men. But, less is known about gender 
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impact on left atrial (LA) and LV response to milder degrees of AS.
Methods: Echocardiography was performed at baseline in 1095 men and 687 women aged 
28-86 (mean 67±10) years with asymptomatic AS recruited into the Simvastatin Ezetimibe 
in Aortic Stenosis (SEAS) study. The study population was divided into tertiles of peak 
transaortic velocity (Table 1). LV hypertrophy was considered present if LV mass/body 
surface area >104g/m2 in women and >116 g/m2 in men; concentric geometry if relative wall 
thickness >0.43; and enlarged LA if diameter >3.8 cm in women and >4.2 cm in men.
Results: Prevalence of normal LV geometry decreased in both genders with increasing 
degree of AS. Men had higher prevalence of LV hypertrophy in all groups despite younger 
age, lower systolic blood pressure and larger aortic valve area/body surface area (AVAI) 
compared to women (all p<0.01). Concentric geometry was not more common in women. 
LA diameter increased with severity of AS in women (p<0.05). Dilated LA was more 
common in women with more severe AS.
Conclusion: Among patients with asymptomatic AS, women have 1) less LV hypertrophy 
despite higher age and systolic blood pressure and smaller AVAI than men; 2) more LA 
dilatation; 3) no preponderance of concentric LV geometry. The results must be further 
studied prospectively.
Group 1 Group 2 Group 3
Transaortic velocity m/s 1.61-2.79 2.80-3.33 3.34-4.76
Gender Women Men Women Men Women Men
LV hypertrophy % 19* 28 23* 32 33 39
Concentric geometry % 18 15 14** 20 19 21
LA (cm) 3.58±0.63* 3.83±0.63 3.55±0.68* 3.82±0.64 3.72±0.67** 3.85±0.67
Dilated LA % 32 27 32 25 45* 30
AVAI (cm²/m²) 0.75±0.21* 0.83±0.26 0.62±0.18* 0.66±0.20 0.53±0.16* 0.57±0.19
*p<0.01, **p<0.05 between genders within group
1030-20 Prognostic Value of N-terminal Pro B-type Natriuretic 
Peptide (NT-proBNP) in Conservatively Treated Patients 
With Valvular Aortic Stenosis
Michael Weber, Michael Hausen, Roman Arnold, Alexander Berkowitsch, Albrecht 
Elsaesser, Veselin Mitrovic, Christian Hamm, Kerckhoff Heart Center, Bad Nauheim, 
Germany
Background: BNP and NT-proBNP are elevated in patients with aortic valve stenosis 
(AS) related to disease severity. For patients with severe AS a predictive value of BNP 
and NT-proBNP has been shown. However, there are no data available on the predictive 
value of BNP and NT-proBNP in conservatively treated patients. Therefore, we aimed 
to evaluate the prognostic value of NT-proBNP in patients with valvular aortic stenosis 
who are treated conservatively not fulﬁlling the indication for valve surgery compared to 
patients undergoing aortic valve replacement (AVR).
Methods and results: 159 patients were included. Follow up took part after 324 (219-
347) days and 902 (861-952) days. AVR was performed in 102 patients whereas 57 
patients were treated conservatively. In patients with AS NT-proBNP at baseline was 
elevated associated to the degree of severity (AS I 301 (135-472) pg/ml, AS II 466 (145-
1054) pg/ml and AS III 1035 (473-2980) pg/ml; p<0.001). During the follow up period 
21 patients (13%) died for cardiovascular reasons or required rehospitalisation because 
of decompensated heart failure. NT-proBNP at baseline was higher in patients with 
an adverse outcome compared to event free survivors 623 (204-1854) pg/ml vs. 1054 
(687-2960) pg/ml; p=0.028). This difference was even more obvious in conservatively 
treated patients (331 (129-881) pg/ml vs. 1102 (796-2960) pg/ml; p=0.002). In contrast no 
difference was present in patients undergoing AVR (865 (331-2840) pg/ml vs. 743 (434-
1482) pg/ml; p=0.803). NT-proBNP with a cut-off value of 640 pg/ml was an independent 
predictor for an adverse outcome in the entire study group and even more marked in 
conservatively treated patients (AUC= 0.65; p=0.028 and AUC=0.82; p=0.002), but was 
without predictive value in those patients undergoing AVR (AUC=0.544).
Conclusion: NT-proBNP is related to severity of AS and provides independent 
prognostic information for an adverse outcome. However, this predictive value is limited to 
conservatively treated patients only. Thus our data suggest that NT-proBNP assessment 
might be of incremental value to decide on the optimal timing of valve replacement.
1030-21 Are There Gender-Related Differences in Presentation 
and Management of Patients with Severe Aortic 
Stenosis?
Agnes Cachier, Bernard Iung, David Messika-Zeitoun, Christa Gohlke-Bärwolf, Gabriel 
Baron, Francois Delahaye, Dominique Himbert, Alec Vahanian, Bichat Hospital, Paris, 
France
Background: Little is known on the impact of gender-related differences in the 
presentation and management of aortic stenosis (AS). We compared men and women 
with severe AS in the Euro Heart Survey on valvular heart disease.
Methods: Of 5001 patients included, 1197 had AS, among whom 809 had severe AS, deﬁned 
as indexed valve area (VA)≤0.6 cm²/m² body surface area or mean gradient ≥50 mmHg.
Results: Patient characteristics are detailed in the Table. A decision to operate was 
taken in 73% of women and 76% of men (p=0.38). In multivariate analysis, a decision 
not to operate was associated with age ≥80 years (Odds-ratio 2.9, 95% CI [1.8-4.7], 
p<0.0001), NYHA class I-II (OR 1.6, 95% CI [1.1-2.4], p=0.01), the presence of at least 
one comorbidity (OR 1.5, 95% CI [1.1-2.2], p=0.03), and LV ejection fraction <50% (OR 
1.6, 95% CI [1.0-2.5], p=0.04), but not with gender (OR 0.9, 95% CI [0.6-1.3], p=0.59).
Of the 410 patients who had undergone surgery during the study period, 30-day mortality 
was 1.8% in women and 4.2% in men (p=0.17). One-year survival was 98±2% in men 
and 94±3% in women (p=0.09).
Conclusion: This contemporary survey shows that 1) Women with severe AS present at 
an older age and with more severe symptoms, while men have more frequent comorbidity 
and coronary disease. 2) The severity of AS does not differ according to gender when 
considering indexed valve area. 3) Gender has no impact on the decision to operate, 
even when adjusting for differences in patient characteristics 4) One-year survival tended 
to be higher in women.
Comparison of men and women with severe aortic stenosis
Women
(n=347)
Men
(n=462) p
Age (years) 72±10 68±12 <0.001
Age >=80 years (%) 20 9 <0.001
NYHA class III-IV (%) 48 37 0.002
Angina (%) 45 49 0.26
At least one comorbidity (%) 30 40 0.002
Coronary disease (%) 35 48 <0.001
Left ventricular ejection farction 0.60±0.12 0.56±0.14 <0.001
Indexed valve area (cm²/m²) 0.41±0.19 0.41±0.10 0.49
1030-22 Aortic Valve Replacement in Patients With Moderate 
to Severe Aortic Stenosis Does Not Prevent Bleeding 
From Gastrointestinal Arteriovenous Malformations
Dali Feng, Gautam Ramakrishna, Maurice F. Sarano, Todd H. Baron, Patricia A. Pellikka, 
Joseph F. Malouf, Mayo Clinic, Rochester, MN
Background: The association between native aortic valvular stenosis (AS) and 
bleeding from arteriovenous malformations (AVM) of the gastrointestinal (GI) tract 
(Heyde’s syndrome) remains controversial. Small studies suggested that severe AS was 
associated with consumption of high molecular weight von Willebrand factor (vWF) which 
might contribute to GI bleeding. Aortic valve replacement (AVR) has been suggested as 
a potential solution to prevent recurrent AVM bleeding, but data other than case reports 
are lacking. We therefore, sought to evaluate the relationship between AVR for AS and 
bleeding AVM.
Methods: We retrospectively matched the endoscopic database (1996-2004) to the 2D 
echo database at Mayo Clinic and identiﬁed patients who had native AS that was either 
moderate (trans-valvular mean gradient 30-49 mmHg and/or aortic valve area 1-1.5 cm2) 
or severe (mean gradient ≥ 50 mmHg and/or aortic valve area <1.0 cm2 and/or peak aortic 
velocity > 4.5 cm/s), and AVM. AVM was considered present if angioectasia or vascular 
malformation was documented by endoscopy.
Results: We identiﬁed 1411 endoscopically proven AVM patients. 43 patients had either 
moderate (n=22) or severe (n=21) AS (age at index endoscopy 78 ± 9 years, 58% male). 
12 patients who did not undergo AVR were excluded. The remaining 31 patients (76 ± 9 
years; severe AS in 20 patients) underwent AVR (bioprosthetic valve in 22/31 patients, 
71%). AVM was ﬁrst diagnosed pre-AVR in 8 patients (1.7 ± 2.9 years, 7 with severe 
AS) and post-AVR in 23 patients (3.7 ± 4.1 years, 13 with severe AS). Thirteen of the 
31 AVR patients (39%) including 3 of 8 the patients with a pre AVR diagnosis of AVM, 
experienced AVM bleeding at a median of 4.1 years from time of AVR. Four of the13 
patients had therapeutic (n=3 with INR 2-3) or supra-therapeutic anticoagulation (n=1 
with INR 3.1). The remaining 9 patients had sub-therapeutic (INR<2, n=5) anticoagulation 
or were not on anticoagulants (n=4) at the time of AVM bleeding. The use of warfarin was 
not associated with increased risk of bleeding, p>0.05.
Conclusions: The hypothesis that AVR prevents AVM bleeding in AS patients is not 
supported by our data. Further prospective studies in larger numbers of patients are 
needed.
1030-23 Speciﬁc Effects of Statins on Gene- Proﬁling in Human 
End- Stage Stenotic Calciﬁed Aortic Valves
Thomas Anger, Lukas Kandler, Thomas Barthel, Theodor Fischlein, Werner G. Daniel, 
Falk K. Pohle, Christoph D. Garlichs, Department of Cardiology, Erlangen, Germany, 
Center of Cardiac Surgery, Erlangen, Germany
Background: Sclerotic calciﬁcation of the aortic valve is a common disease in advanced 
age. Pathophysiologic processes leading to valve calciﬁcations are poorly understood. 
Common similarities between inﬂammatory processes in atherosclerotic lesions and 
molecularbiological processes leading to valve sclerosis are shown and therapeutical 
approaches other then valve replacement are part of investigations. Recently, prospective 
potent statin treatment of aortic valve sclerosis showed only rare reduction on clinical 
progression. To further clarify the pathophysiological changes within end-stage stenotic 
calciﬁed aortic valves in order to ﬁnd new pharmacological targets, we investigated gene-
proﬁling using microarray and real-time PCR on parameters of inﬂammation.
Methods: Severe calciﬁed and stenotic aortic valves from patients without (CSAV-) and with 
statins prior valve replacement (CSAV+) were collected. Valves from patients with type A 
aortic dissection were considered as controls. RNA Isolation was carried out and microarray 
using pooled samples was performed. Real-time PCR conﬁrmed all detected results.
Results: More then 2.0 fold upregulated were eotaxin 3, monokine induced by gamma-
interferon, vascular adhesion protein-1 (VAP-1), peroxisome proliferative activated 
receptor-alpha or transforming growth factor-beta (TGF-b). In contrast, we found 
signiﬁcant downregulation of vascular cell adhesion molecule-1, interleukin-4, tissue 
inhibitor of metalloproteinase 3 or caspase 8. In addition aortic valves pre-treated with 
statins showed no signiﬁcant change in gene expression over control for previously 
mentioned genes of inﬂammation except for TGF-b and VAP-1.
Conclusions: In end- stage calciﬁed stenotic aortic valves this study deﬁnes still 
continuing atherosclerotic inﬂammatory gene expression to a low extend - potently 
inﬂuenced through Statins. But our data support the clinical observation showing only 
little beneﬁt on progression of statins on end- stage aortic valve disease. In addition, we 
hypothize, that the antiinﬂammatoriy effect of statins may have its beneﬁt in early stages 
of calciﬁed aortic valves.
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1030-24 Comorbidities in Severe Aortic Valve Stenosis: Do 
Renal Dysfunction, Anemia or Diabetes Mellitus Predict 
Long-Term Outcome?
Christian Bruch, Daniela Kauling, Holger Reinecke, Markus Rothenburger, Thomas 
Wichter, Hospital of the University of Muenster, Muenster, Germany
Aim In patients (pts) with severe aortic valve stenosis (valve area ≤ 1 cm2, AS), the 
clinical status and echocardiographic variables carry prognostic information. In such pts, 
the impact of comorbidities on long-term outcome is unclear.
Methods Fifty-ﬁve pts with severe AS (mean aortic valve area 0.7±0.3 cm2, mean age 
70±10 years), who underwent cardiac catheterization and 2-D/Doppler echocardiography, 
were prospectively enrolled. The baseline glomerular ﬁltration rate (GFR) was calculated 
using the Cockroft Gault equation. Diabetes mellitus was diagnosed according to WHO 
criteria. Death from a cardiac cause was deﬁned as study end point.
Results Cardiac catheterization revealed concomitant coronary artery disease (CAD) 
in 29 pts (53%). Subsequently, 42 pts. underwent aortic valve replacement (22 with 
CA bypass grafting). During a follow-up of 485±336 days, 11 pts suffered a cardiac 
death. Survivors and non-survivors did not differ with respect the prevalence of CAD or 
echocardiographic measures of systolic/diastolic function. Non-survivors were in a poorer 
NYHA functional class (3.1±0.3 vs. 2.4±0.7, p=0.02), had a lower GFR (37.9±14.7 ml/
min/1.73m2 vs. 61.3±24.2 ml/min/1.73m2 , p=0.004 ), a higher prevalence of diabetes 
mellitus (72.7% vs. 23.8%, p=0.01) and a lower serum hemoglobin level (11.6±2.1 vs. 
12.9±1.5 g/dL, p=0.025). On univariate Cox analysis, age, NYHA class, GFR, diabetes 
mellitus and serum hemoglobin level were signiﬁcantly associated with the study end 
point. Multivariate analysis identiﬁed NYHA class (hazard ratio: 11.5; 95% CI 2.15-
51.6, p=0.003) and GFR (hazard ratio 0.96, 95% CI 0.92-0.99, p=0.03) as independent 
prognostic predictors. In pts with GFR < 39 ml/min/1.73m2 (cut-off value derived from 
ROC analysis; area under the ROC curve 0.77±0.07), outcome was markedly poorer as 
compared with to pts with GFR > 39 ml/min/1.73m2 (event-free survival rate 25.3% vs. 
93.6%, p<0.001 by logrank analysis).
Conclusions In pts with severe AS, comorbidities, particularly renal dysfunction, 
signiﬁcantly impact on long-term outcome. Early diagnosis and treatment of comorbidities 
may help to improve prognosis in this patient population.
1030-25 Atherosclerosis of the Aorta Is Strongly Associated 
With Calciﬁc Aortic Valve Stenosis Independently of 
Classical Atherosclerosis Risk Factors
Roberto Martin, Violeta Sanchez, Rocio Tello de Meneses, Sagrario Fernandez, 
Federico Lombera, Javier Jimenez, Juan F. Delgado, Agustin Gomez de la Camara, 
Carlos Saenz, Doce de Octubre Hospital, Madrid, Spain
Background: Previous studies of aortic valve disease have found association with 
atherosclerosis risk factors. Besides, an increased incidence of aortic atherosclerosis has 
been described in patients with aortic stenosis.
Objectives: The aim of this study was to determine the relation between aortic valve 
calciﬁcation and aortic atherosclerosis studied by transesophageal echocardiography 
and the inﬂuence of classical atherosclerosis risk factors.
Methods: Between 2001 and 2005, 65 patients (30 women) with moderate to severe 
aortic stenosis undergoing transesophageal echocardiography were enrolled. Aortic valve 
calciﬁcation score (AVCS) was graded from 1-4 (Rosenhek classiﬁcation). The aorta was 
completed imaged from the root to the level of the diaphragm. For the severity of aortic 
atherosclerosis we used Montgomery classiﬁcation (grade I = normal; grade II = intimal 
thickening; grade III = atheroma <5 mm; grade IV = atheroma ≥5 mm; grade V = mobile lesion). 
Relation between AVCS and aortic atherosclerosis just as risk factors were analysed.
Results: Baseline characteristics were: mean age 71.7 ± 8 years, arterial hypertension 
34%, diabetes mellitus 13%, impaired renal function 20%, coronary artery disease 21%, 
hypercholesterolemia 43% and smoking history 20%. Thirty-seven patients had severe 
aortic stenosis and 28 moderate aortic stenosis. Mean peak ﬂow velocity across de valve 
was 4.55 m/sec (range 3 to 6). AVCS was: grade 1 = 3% (n = 2), grade 2 = 48% (n 
= 31), grade 3 = 40% (n = 26) and grade 4 = 9% (n = 6). Incidence of severe aortic 
atherosclerosis (grade ≥ IV) was 17%. A strong correlation was found between AVCS and 
aortic atherosclerosis severity (r = 0.57, p < 0.0001). In the multivariate analysis aortic 
atherosclerosis severity was the only independent variable associated with advanced 
AVCS (OR 13.7, 95% CI 2.9, 64.2).
Conclusions: In aortic valve stenosis, aortic atherosclerosis disease is strongly 
associated with AVCS. The lack of association with classical atherosclerosis risk factors 
suggests that aortic valve disease and thoracic aorta atherosclerosis share similar 
pathophysiological mechanisms independent of atherosclerosis risk factors.
1030-26 Association of Low Fetuin-A and Inﬂammation With the 
Severity of Aortic Valve Calciﬁcation
Ralf Koos, Harald Peter Kuehl, Andreas Horst Mahnken, Georg Muehlenbruch, Joachim 
Ernst Wildberger, Markus Ketteler, Vincent Brandenburg, University Hospital RWTH 
Aachen, Aachen, Germany
Background: The aim of the present study was to investigate the relationship between the 
serum fetuin-A (alpha2-Heremans Schmid glycoprotein) level as well as the high sensitive 
C-reactive protein (hsCRP) level and the amount of aortic valve calcium (AVC) assessed 
by retrospectively ECG-gated Multislice Spiral Computed Tomography (MSCT).
Methods: In a prospective cross-sectional study 104 consecutive non-dialyzed patients 
(mean age 71 ± 8 years,78 men) with echocardiographically proven calciﬁc aortic valve 
disease were investigated. In all patients (pts) hsCRP was determined by means of 
particle-enhanced immunonephelometry. Serum fetuin-A levels were measured by 
nephelometry (BNII, Dade Behring Holding, Liederbach, Germany) using a polyclonal 
rabbit anti-human antibody against fetuin-A. For quantiﬁcation of AVC all pts underwent 
16-slice MSCT (Sensation 16, Siemens, Forchheim, Germany;scan parameters: 420ms 
tube rotation time, 12x 0.75mm collimation). Images were reconstructed at 60% of the RR 
interval with an effective slice thickness of 3mm and a reconstruction increment of 2mm. 
AVC was assessed using Agatston AVC score.
Results: There was no correlation between serum fetuin-A levels and the amount of AVC. 
Patients with hsCRP concentrations above the median (6.38mg/l) showed signiﬁcantly 
higher Agatston AVC scores (1584 ± 1625) than patients with hsCRP levels below the 
median (900 ± 941, p=0.01). In addition, patients were stratiﬁed into 4 groups based on 
hsCRP and fetuin-A levels above (+) or below (-) the median. Patients with low fetuin-
A and high hsCRP (fet-/CRP+) concentrations showed signiﬁcantly higher Agatston 
AVC scores (1976 ± 1773) than patients with low fetuin-A and low hsCRP (fet-/CRP-) 
levels (656 ± 688, p<0.001) or patients with high fetuin-A and high hsCRP (fet+/CRP+) 
concentrations (1063 ± 1179, p=0.03) and patients with high fetuin-A and low hsCRP 
(fet+/CRP-) levels (952 ± 961, p=0.006).
Conclusion: The combination of high levels of hsCRP indicating systemic inﬂammation 
plus low fetuin-A serum levels indicating systemic calciﬁcation inhibitor deﬁciency were 
associated with pronounced aortic valve calciﬁcation.
1030-27 Features of the Metabolic Syndrome and Diabetes 
Mellitus as Predictors of Aortic Valve Calciﬁcation as 
Detected by Electron Beam Computed Tomography in 
the Multi-Ethnic Study of Atherosclerosis
Ronit Katz, Nathan D. Wong, Matthew J. Budoff, Richard Kronmal, Junichiro Takasu, 
David M. Shavelle, Alain G. Bertoni, Jeffrey L. Probstﬁeld, Kevin D. O’Brien, University of 
Washington, Seattle, WA, Harbor-UCLA Medical Center, Torrance, CA
Background: Calciﬁc aortic valve disease is common in the elderly, is correlated with 
cardiovascular risk factors, and is associated with increased cardiovascular event risk. 
However, whether the metabolic syndrome (MetS) is associated with an increased 
prevalence of aortic valve calcium (AVC) is not known.
Methods: The prevalence of aortic valve calcium (AVC) was compared in 6,780 Multi-
Ethnic Study of Atherosclerosis (MESA) participants with MetS (n=1,550, ATP III criteria), 
diabetes (n=1,016), or neither condition (n=4,024). The prevalence of AVC for those with 
neither condition, MetS, or diabetes was, respectively, 8%, 12%, and 17% in women 
(p<0.001) and 14%, 22%, and 24% in men (p<0.001). Relative risk (RR) estimates are 
presented from the model y=exp(BTX), rather than odds ratios (ORs) because of the high 
prevalence of calciﬁcation (>10%) in the cohort.
Results: As compared to those with neither condition, the adjusted relative risks for the 
presence of AVC were 1.45 (95% CI 1.11 to 1.90) for MetS and 2.12 (95% CI 1.54 to 2.92) 
for diabetes and 1.70 (95% CI 1.32 to 2.19) for Mets and 1.73 (95% CI 1.33 to 2.25) for 
diabetes in men (models were adjusted for age, race, LDL cholesterol , smoking, and lipid 
lowering medication). There was a graded, linear relationship between AVC prevalence 
and the number of MetS components in both women and men (both p<0.001). Similar 
results were obtained using the IDF deﬁnition of MetS.
Conclusions: In the MESA cohort, MetS and diabetes are associated with increased risk 
of AVC and AVC prevalence is increased with increasing number of MetS components. 
These ﬁndings suggest that MetS is a risk factor for AVC and raises the possibility that 
interventions targeting MetS might decrease AVC progression.
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